## Revolade®

Thrombopoietin-receptor agonist

## DESCRIPTION AND COMPOSITION

### Pharmaceutical form

### Film-coated tablets

The 25 mg tablets are white, round, biconvex, and film-coated, debossed with 'GS NX3' and '25' on one side.

Certain dosage strengths and dosage forms may not be available in all countries.

### Active substance

Each film-coated tablet contains eltrombopag olamine equivalent to 25 mg of eltrombopag as eltrombopag free acid.

### Excipients

Film-coated tablets

**Tablet core**

Microcrystalline cellulose

Mannitol

Sodium starch glycolate

Magnesium stearate

Povidone

### Tablet coating

25 mg tablets: Hypromellose, Macrogol (polyethylene glycol), Titanium dioxide (E171), Polysorbate 80

Pharmaceutical formulations may vary between countries.

## INDICATIONS

Revolade is indicated:

- for the treatment of previously treated adult and pediatric patients 1 year and older with immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis who have failed treatment with steroids and platelet count below 30,000/mm$^3$ with clinical bleeding.

- in patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia to:
  - enable the initiation of interferon based therapy
  - optimize interferon based therapy

- in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia (first-line SAA).

- for the treatment of cytopenias in patients with severe aplastic anemia (refractory SAA) who have had an insufficient response to immunosuppressive therapy.

## DOSAGE REGIMEN AND ADMINISTRATION

Revolade treatment should remain under the supervision of certified hematologists only.

### Dosage regimen

Revolade dosing regimens must be individualized based on the patient's platelet counts.

### General target population

### Immune thrombocytopenia

The lowest dose of Revolade should be used to achieve and maintain a platelet count ≥50,000/microL. Dose adjustments are based upon the platelet count response. Revolade should not be used to normalize platelet counts. In clinical studies, platelet counts generally increased within 1 to 2 weeks after starting Revolade and decreased within 1 to 2 weeks after discontinuation.

### Initial dose regimen

### Adults and pediatric patients aged 6 to 17 years

The recommended starting dose of Revolade is 50 mg once daily.

For adult and pediatric ITP patients aged 6 to 17 years of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 25 mg once daily (see section CLINICAL PHARMACOLOGY, section SPECIAL POPULATIONS).

### Pediatric patients aged 1 to 5 years

The recommended starting dose of Revolade is 25 mg once daily.

For pediatric ITP patients aged 1 to 5 years of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 25 mg once daily (see section CLINICAL PHARMACOLOGY, section SPECIAL POPULATIONS).

## Monitoring and dose adjustment

### Adults and pediatric patients aged 1 to 17 years

After initiating Revolade, the dose should be adjusted to achieve and maintain a platelet count ≥50,000/microL as necessary to reduce the risk for bleeding. A daily dose of 75 mg should not be exceeded.

Clinical hematology and liver function tests should be monitored regularly throughout therapy with Revolade and the dose of Revolade should be modified based on platelet counts as outlined in Table 1. During therapy with Revolade complete blood counts (CBCs), including platelet count and peripheral blood smears, should be assessed weekly until a stable platelet count (≥50,000/microL for at least 4 weeks) has been achieved. CBCs including platelet count and peripheral blood smears should be obtained monthly thereafter.

**Table 1          Revolade dose adjustments in ITP patients**

| Platelet count | Dose adjustment or response |
|---|---|
| <50,000/microL following at least 2 weeks of therapy | Increase daily dose by 25 mg to a maximum of 75 mg/day#. |
| ≥200,000/microL to ≤400,000/microL | Decrease the daily dose by 25 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments*. |
| >400,000/microL | Discontinue Revolade; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150,000/microL, reinitiate therapy at a lower daily dose*. |

# For patients taking 25 mg Revolade once every other day, increase dose to 25 mg once daily.

* For patients taking 25 mg Revolade once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively a dose of 25 mg once every other day.

The standard dose adjustment, either decrease or increase, would be 25 mg once daily. However, in a few patients, a combination of different tablet strengths on different days or less frequent dosing may be required.

After any Revolade dose adjustment, platelet counts should be monitored at least weekly for 2 to 3 weeks. To see the effect of any dose adjustment on the patient's platelet response prior to considering another dose increase, one should wait for at least 2 weeks. In patients with liver cirrhosis (i.e., hepatic impairment), one should wait 3 weeks before increasing the dose (see section DOSAGE REGIMEN AND ADMINISTRATION, SPECIAL POPULATIONS, section HEPATIC IMPAIRMENT).

## Discontinuation

### Adults and pediatric patients aged 1 to 17 years

Treatment with Revolade should be discontinued if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks of therapy at 75 mg once daily.

## Chronic hepatitis C (HCV) associated thrombocytopenia

When Revolade is given in combination with antiviral therapies reference should be made to the full prescribing information of the respective co-administered medicinal products for comprehensive details of administration.

The lowest dose of Revolade to achieve and maintain a platelet count necessary to initiate and optimize antiviral therapy should be used. Dose adjustments should be based upon the platelet count response. Revolade should not be used to normalize platelet counts. In clinical studies, platelet counts generally increased within 1 week of starting Revolade.

## Initial dose regimen

### Adults

Revolade should be initiated at a dose of 25 mg once daily.

For chronic HCV patients of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 25 mg once daily (see section CLINICAL PHARMACOLOGY and section SPECIAL POPULATIONS).

### Monitoring and dose adjustment

The dose of Revolade should be adjusted in 25 mg increments every 2 weeks as necessary to achieve the target platelet count required to initiate antiviral therapy (see Table 2). Platelet counts should be monitored every week prior to starting antiviral therapy.

During antiviral therapy the dose of Revolade should be adjusted as necessary to avoid dose reduction of peginterferon. Platelet counts should be monitored weekly during antiviral therapy until a stable platelet count is achieved. CBCs, including platelet counts and peripheral blood smears should be obtained monthly thereafter.

A dose of 100 mg Revolade once daily should not be exceeded.

For specific dosage instructions for peginterferon alfa or ribavirin, one should refer to their respective prescribing information.

**Table 2          Revolade dose adjustments in HCV patients during antiviral therapy**

| Platelet count | Dose adjustment at 2-weekly intervals |
| --- | --- |
| <50,000/microL | Increase daily dose by 25 mg up to a maximum dose of 100 mg. |
| ≥50,000/microL to ≤200,000/microL | Administer the lowest effective dose of Revolade necessary to avoid dose reductions of peginterferon. |
| >200,000/microL to ≤400,000/microL | Decrease the daily dose by 25 mg. Wait 2 weeks to assess the effects of this and adjust dose as necessary. Platelet counts may fall upon initiation of antiviral therapy, so immediate Revolade dose reductions should be avoided. |

| Platelet count | Dose adjustment at 2-weekly intervals |
|---|---|
| >400,000/microL | Discontinue Revolade and increase the frequency of platelet monitoring to twice weekly. Once the platelet count is ≤150,000/microL, reinitiate therapy at a daily dose reduced by 25 mg. For patients on 25 mg Revolade reduce to 12.5 mg once daily. |

For patients taking 25 mg Revolade once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively a dose of 25 mg once every other day.

## Discontinuation

In patients with HCV genotype 1/4/6, independent of the decision to continue interferon therapy, discontinuation of Revolade therapy should be considered in patients who do not achieve virological response at week 12. If HCV-RNA remains detectable after 24 weeks of treatment, Revolade therapy should be discontinued.

Revolade treatment should be terminated when antiviral therapy is discontinued. Excessive platelet count responses, as outlined in Table 2, or important liver test abnormalities may also necessitate discontinuation of Revolade (see section WARNINGS AND PRECAUTIONS).

## First-line severe aplastic anemia

Revolade should be initiated concurrently with standard immunosuppressive therapy.

The initial dose of Revolade should not be exceeded.

### Initial dose regimen

## Adult and adolescent patients aged 12 to 17 years

The recommended initial dose of Revolade is 150 mg once daily for 6 months.

For adult and adolescent SAA patients of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 75 mg once daily for 6 months.

## Pediatric patients aged 6 to 11 years

The recommended initial dose of Revolade is 75 mg once daily for 6 months.

For pediatric SAA patients of East-/Southeast-Asian ancestry aged 6 to 11 years, Revolade should be initiated at a dose of 37.5 mg once daily for 6 months.

## Pediatric patients aged 2 to 5 years

The recommended initial dose of Revolade is 2.5 mg/kg once daily for 6 months.

For pediatric SAA patients of East-/Southeast-Asian ancestry aged 2 to 5 years, Revolade should be initiated at a dose of 1.25 mg/kg once daily for 6 months.

**Table 3        Dose of standard immunosuppressive therapy administered with Revolade in the first-line SAA pivotal study (see section Clinical studies)**

| Agent | Dose administered in the pivotal study |
|---|---|
| Horse antithymocyte globulin (h-ATG) | 40 mg/kg/day, based on actual body weight, administered intravenously on Days 1 to 4 of the 6-month treatment period. |
| Cyclosporine* <br><br> (Therapeutic dose for 6 months, from Day 1 to Month 6, adjusted to obtain a target therapeutic trough level between 200 and 400 micrograms/L) | <u>Patients aged 12 years and older:</u> <br><br> 3 mg/kg, based on actual body weight, orally every 12 hours (total daily dose of 6 mg/kg/day) for 6 months, starting on Day 1. <br><br> *Patients >20 years of age with a body mass index >35 or patients aged 12 to 20 years with a body mass index >95th percentile:* <br><br> 3 mg/kg, based on adjusted body weight#, orally every 12 hours (total daily dose of 6 mg/kg/day) for 6 months, starting on Day 1. <br><br> <u>Pediatric patients aged 2 to 11 years:</u> <br><br> 6 mg/kg, based on actual body weight, orally every 12 hours (total daily dose of 12 mg/kg/day) for 6 months, starting on Day 1. <br><br> *Patients with a body mass index >95th percentile:* <br><br> 6 mg/kg, based on adjusted body weight#, orally every 12 hours (total daily dose of 12 mg/kg/day) for 6 months, starting on Day 1. |
| Cyclosporine <br><br> (Maintenance dose, from Month 6 to Month 24) | <u>For patients who achieve a hematologic response at 6 months:</u> <br><br> 2 mg/kg/day administered orally at a fixed dose for an additional 18 months. |
| *\* Dose of cyclosporine may need to be adjusted to achieve the above recommended target trough levels when cyclosporine is used concomitantly with other therapies; refer to the appropriate cyclosporine prescribing information.* <br> *# Calculated as the midpoint between the ideal body weight and actual body weight.* | |

**Monitoring and dose adjustment**

Clinical hematology and liver tests should be performed regularly throughout therapy with Revolade.

The dosage regimen of Revolade should be modified based on platelet counts as outlined in Table 4.

Table 5 summarizes the recommendations for dose interruption, reduction, or discontinuation of Revolade in the management of liver function abnormalities and thrombosis/embolism events.

**Table 4        Revolade dose adjustments in first-line SAA**

| Platelet count result | Dose adjustment or response |
|---|---|
| >200,000/microL to ≤400,000/microL | Decrease the daily dose by 25 mg every 2 weeks to lowest dose that maintains platelet count ≥50,000/microL.<br><br>In pediatric patients under 12 years of age, decrease the dose by 12.5 mg*. |
| >400,000/microL | Discontinue Revolade for one week.<br><br>Once the platelet count is <200,000/microL, reinitiate Revolade at a daily dose reduced by 25 mg (or 12.5 mg in pediatric patients under 12 years of age)*. |
| * *For patients taking 25 mg Revolade once daily, consideration should be given to dosing at 12.5 mg once daily or alternatively a dose of 25 mg once every other day.* | |

**Table 5        Recommended dose modification for liver function abnormalities and thrombosis/embolism in first-line SAA patients**

| Event | Recommendation |
|---|---|
| Liver function abnormalities | Increase in ALT >6 times the upper limit of normal (x ULN):<br>Discontinue Revolade.<br>Once ALT is <5 x ULN, reinitiate Revolade at the same dose.<br><br>Increase in ALT >6 x ULN after reinitiating Revolade (and is not attributable to other inciting factors, e.g., serum sickness, sepsis, or azole antifungal agents):<br>Monitor ALT at least every 3 to 4 days.<br><br>If ALT remains >6 x ULN on repeat blood tests:<br>Discontinue Revolade.<br>Once ALT is <5 x ULN, reinitiate Revolade at a daily dose reduced by 25 mg compared to the previous dose.<br><br>If ALT returns to >6 x ULN on the reduced dose:<br>Reduce the daily dose of Revolade by 25 mg until ALT is <5 x ULN.<br><br>There is no data on dose modification due to liver function abnormalities in pediatric patients. Dose modification proportional to that in adults (e.g., 12.5 mg) should be considered based on clinical judgement. |
| Thrombosis/embolism | Deep vein thrombosis (DVT), pulmonary embolus (PE), transient ischemic attack (TIA) or stroke, myocardial infarction at any time while on Revolade:<br>Discontinue Revolade but remain on h-ATG and cyclosporine. If the platelet level is >50,000/microL at the time of thrombosis, treatment with enoxaparin or another appropriate anticoagulant is recommended as clinically indicated until the platelet count drops <20,000/microL or a standard 3 to 6 month course of anticoagulation is completed. |

**Discontinuation**

The total duration of Revolade treatment is 6 months.

Excessive platelet count responses (as outlined in Table 4) or certain adverse events (as outlined in Table 5) also necessitate discontinuation of Revolade.

### Refractory severe aplastic anemia

### Initial dose regimen

### Adults

Revolade should be initiated at a dose of 50 mg once daily.

For SAA patients of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 25 mg once daily (see section CLINICAL PHARMACOLOGY, SPECIAL POPULATIONS).

### Monitoring and dose adjustment

Hematological response requires dose titration, generally up to 150 mg, and may take up to 16 weeks after starting Revolade (see section CLINICAL STUDIES). The dose of Revolade should be adjusted in 25 mg increments every 2 weeks as necessary to achieve the target platelet count ≥50,000/microL. A dose of 150 mg daily should not be exceeded. Clinical hematology and liver tests should be monitored regularly throughout therapy with Revolade and the dosage regimen of Revolade should be modified based on platelet counts as outlined in Table 6.

**Table 6          Revolade dose adjustments in refractory SAA patients**

| Platelet Count Result | Dose Adjustment or Response |
|---|---|
| <50,000/microL following at least 2 weeks of therapy | Increase daily dose by 25 mg to a maximum of 150 mg/day. |
| ≥100,000/microL to ≤200,000/microL at any point during therapy | Decrease the daily dose by 50 mg. Wait 2 weeks to assess the effects of this and any subsequent dose adjustments. |
| >200,000/microL | Discontinue Revolade for at least one week. Once the platelet countis <150,000/microL, reinitiate therapy at a daily dose reduced by 50 mg. |
| >200,000/microL after 2 weeks of therapy at lowest dose of Revolade | Discontinue Revolade. Reinitiate therapy with 25 mg or the next lower dose once the platelet count is <50,000/microL. |

### Tapering for tri-lineage (white blood cells, red blood cells, and platelets) responders

Once platelet count is >50,000/microL, hemoglobin is >10 g/dL in the absence of red blood cell (RBC) transfusion, and absolute neutrophil count (ANC) is $>1 \times 10^9$/L for more than 8 weeks, the dose of Revolade should be reduced by up to 50%. If counts stay stable after 8 weeks at the reduced dose, then Revolade should be discontinued and blood counts monitored. If platelet counts drop to <30,000/microL, hemoglobin drops to <9 g/dL or ANC to <0.5 x $10^9$/L, Revolade may be reinitiated at the previous dose.

### Discontinuation

If no hematological response has occurred after 16 weeks of therapy with Revolade, therapy should be discontinued. Discontinuation should be considered if new cytogenetic abnormalities

are observed (see section ADVERSE DRUG REACTIONS). Excessive platelet count responses (as outlined in Table 6) or important liver test abnormalities also necessitate discontinuation of Revolade (see section WARNINGS AND PRECAUTIONS).

## Special populations (all indications)

### Renal impairment

No dose adjustment is necessary in patients with renal impairment. However, because of limited clinical experience, patients with impaired renal function should use Revolade with caution and close monitoring (see section CLINICAL PHARMACOLOGY and section SPECIAL POPULATIONS).

### Hepatic impairment

ITP patients with liver cirrhosis (hepatic impairment, Child-Pugh score ≥5) should use Revolade with caution and close monitoring (see section WARNINGS AND PRECAUTIONS, section CLINICAL PHARMACOLOGY and section SPECIAL POPULATIONS).

If the use of Revolade is deemed necessary for ITP patients with hepatic impairment the starting dose must be 25 mg once daily. After initiating the dose of Revolade in patients with hepatic impairment, one should wait 3 weeks before increasing the dose.

Chronic HCV patients with hepatic impairment and refractory severe aplastic anemia patients with hepatic impairment should initiate Revolade at a dose of 25 mg once daily (see section CLINICAL PHARMACOLOGY and section SPECIAL POPULATIONS).

In a clinical study in definitive immunosuppressive therapy-naïve severe aplastic anemia, patients with baseline AST/ALT >5 x ULN were ineligible to participate. The initial dose of Revolade in patients with hepatic impairment in the first-line setting should be determined as necessary based on clinical judgement, tolerability, and close monitoring of liver function.

### Pediatric patients (below 18 years)

The safety and efficacy of Revolade have not been established in pediatric patients with ITP younger than 1 year of age, chronic HCV, refractory SAA, and definitive immunosuppressive therapy-naïve SAA patients younger than 2 years of age (see sections ADVERSE DRUG REACTIONS and CLINICAL STUDIES).

### Geriatric patients (65 years of age or older)

There are limited data on the use of Revolade in patients aged 65 years and older. In the clinical studies of Revolade, overall, no clinically significant differences in safety of Revolade were observed between patients aged 65 years and older compared to younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see section CLINICAL PHARMACOLOGY, SPECIAL POPULATIONS).

**East-/Southeast-Asian patients**

For adult and pediatric patients of East-/Southeast-Asian ancestry, Revolade should be initiated at a dose of 25 mg once daily for the treatment of ITP, HCV-associated thrombocytopenia, and refractory SAA. For the treatment of patients with first-line SAA refer to section DOSAGE REGIMEN AND ADMINISTRATION, INTIAL DOSE REGIMEN).

## Method of administration

Revolade should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cations (e.g., aluminium, calcium, iron, magnesium, selenium, and zinc) (see section INTERACTIONS, DRUG-FOOD/DRINK INTERACTIONS).

Revolade may be taken with food containing little (<50 mg) or preferably no calcium (see section INTERACTIONS, DRUG-FOOD/DRINK INTERACTIONS).

## CONTRAINDICATIONS

Revolade is contraindicated in patients who have a history of hypersensitivity reactions to eltrombopag and/or its excipients.

## WARNINGS AND PRECAUTIONS

There is an increased risk for adverse reactions, including potentially fatal hepatic decompensation and thromboembolic events, in thrombocytopenic HCV patients with advanced chronic liver disease, as defined by low albumin levels ≤3.5 g/dL or model for end stage liver disease (MELD) score ≥10, when treated with eltrombopag in combination with interferon-based therapy. In addition, the benefits of treatment in terms of the proportion achieving sustained virological response (SVR) compared with placebo were modest in these patients (especially for those with baseline albumin ≤3.5 g/dL) compared with the group overall. Treatment with eltrombopag in these patients should be initiated only by physicians experienced in the management of advanced HCV, and only when the risks of thrombocytopenia or withholding antiviral therapy necessitate intervention. If treatment is considered clinically indicated, close monitoring of these patients is required.

The effectiveness and safety of Revolade have not been established for use in other thrombocytopenic conditions including chemotherapy-induced thrombocytopenia and myelodysplastic syndrome (MDS).

**Hepatotoxicity:**

Revolade administration can cause hepatobiliary laboratory abnormalities, severe hepatotoxicity, and potentially fatal liver injury.

**Clinical data**

In clinical studies of adult and pediatric patients (aged 1 to 17 years) with ITP who received Revolade, increases in serum alanine aminotransferase (ALT), aspartate aminotransferase

(AST) and indirect (unconjugated) bilirubin were observed (see section ADVERSE DRUG REACTIONS)

These findings were mostly mild (Grade 1-2), reversible and not accompanied by clinically significant symptoms that would indicate impaired liver function. In the two placebo-controlled Phase III studies in adults with ITP, adverse events of ALT increase were reported in 5.7% and 4.0% of Revolade and placebo-treated patients, respectively. In two placebo-controlled studies in pediatric patients (aged 1 to 17 years) with ITP, ALT ≥3 times the upper limit of normal (x ULN) was reported in 4.7% and 0% of the Revolade and placebo groups, respectively.

In two controlled clinical studies in thrombocytopenic patients with HCV, ALT or AST ≥3 x ULN were reported in 34% and 38% of the Revolade and placebo groups, respectively. Revolade administration in combination with peginterferon/ribavirin therapy is associated with indirect hyperbilirubinemia. Overall, total bilirubin ≥1.5 x ULN was reported in 76% and 50% of the Revolade and placebo groups, respectively.

In a single-arm, open-label clinical study in definitive immunosuppressive therapy-naïve SAA patients who received Revolade concurrently with h-ATG and cyclosporine, ALT or AST >3 x ULN with total bilirubin >1.5 x ULN was reported in 43.5% (40/92) of patients. None of these elevations resulted in discontinuation.

In the single-arm, monotherapy study in patients with refractory SAA, concurrent ALT or AST >3 x ULN with total bilirubin >1.5 x ULN were reported in 5% of patients. Total bilirubin >1.5 x ULN occurred in 14% of patients.

**Dosage adjustment**

In patients with ITP, HCV, and refractory SAA, serum ALT, AST and bilirubin should be measured prior to initiation of Revolade, every 2 weeks during the dose adjustment phase and monthly following establishment of a stable dose. Eltrombopag inhibits UGT1A1 and OATP1B1 (see section CLINICAL PHARMACOLOGY), which may lead to indirect hyperbilirubinemia. If bilirubin is elevated, fractionation should be performed. Abnormal serum liver tests should be evaluated with repeat testing within 3 to 5 days. If the abnormalities are confirmed, serum liver tests should be monitored until the abnormalities resolve, stabilize, or return to baseline levels. Revolade should be discontinued if ALT levels increase (≥3 x ULN) in patients with normal liver function, or ≥3 x baseline (or >5 x ULN, whichever is the lower) in patients with elevations in transaminases before treatment and that are:

- progressive, or
- persistent for ≥4 weeks, or
- accompanied by increased direct bilirubin, or
- accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation.

In the first-line setting of severe aplastic anemia, ALT, AST, and bilirubin should be measured prior to initiation of Revolade. During treatment, increases in ALT levels should be managed as recommended in Table 5.

Caution should be exercised when administering Revolade to patients with hepatic disease. In ITP and refractory SAA patients, a lower starting dose of Revolade should be used when

administering to patients with hepatic impairment (see section DOSAGE REGIMEN AND ADMINISTRATION, HEPATIC IMPAIRMENT).

**Severe liver injury:**

Isolated cases of severe liver injury were identified in clinical studies. The elevation of liver laboratory values improved or resolved following Revolade interruption or discontinuation. No cases of severe liver injury related to Revolade were identified in a clinical study in patients with definitive immunosuppressive therapy-naïve SAA or refractory SAA, however, the number of exposed patients in these indications was limited. As the highest authorized dose is administered to patients in the SAA indications (150 mg/day) and due to the nature of the reaction, drug-induced liver injury might be expected in this patient population.

**Hepatic decompensation (use with interferon):**

Chronic HCV patients with liver cirrhosis may be at risk for hepatic decompensation, some with fatal outcomes, when receiving alpha-interferon therapy. In the two controlled clinical studies in thrombocytopenic patients with HCV, hepatic decompensation occurred more frequently in the Revolade arm (13%) than in the placebo arm (7%). Patients with low albumin levels (<3.5 g/dL) or with a Model for End-Stage Liver Disease (MELD) score ≥10 at baseline had a greater risk of hepatic decompensation. Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation. The respective interferon prescribing information for discontinuation criteria should be referred to. Revolade should be terminated if antiviral therapy is discontinued for hepatic decompensation.

**Thrombotic/thromboembolic complications:**

Platelet counts above the normal range present a theoretical risk for thrombotic/thromboembolic complications. In Revolade clinical studies in ITP, thromboembolic events were observed at low and normal platelet counts.

Caution should be used when administering Revolade to patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, antiphospholipid syndrome). Platelet counts should be closely monitored, and consideration given to reducing the dose or discontinuing Revolade treatment if the platelet count exceeds the target levels (see section DOSAGE REGIMEN AND ADMINISTRATION).

In adult ITP studies, thromboembolic/thrombotic events (TEEs) were observed in 42 out of 763 patients (5.5%). The TEEs included: embolism including pulmonary embolism, deep vein thrombosis, transient ischemic attack, myocardial infarction, ischemic stroke, and suspected prolonged reversible ischemic neurologic deficiency.

No cases of TEEs were identified in a clinical study in refractory SAA patients, however the number of exposed patients in this indication was limited. As the highest authorized dose is administered to patients in the SAA indication (150 mg/day) and due to the nature of the reaction, TEEs might be expected in this patient population.

Revolade should not be used in patients with hepatic impairment (Child-Pugh score ≥5) unless the expected benefit outweighs the identified risk of portal venous thrombosis. When treatment is considered appropriate, caution should be exercised when administering Revolade to patients with hepatic impairment (see section DOSAGE REGIMEN AND ADMINISTRATION AND ADVERSE DRUG REACTIONS, HEPATIC IMPAIRMENT).

In the two controlled Phase III studies in thrombocytopenic patients with HCV receiving interferon-based therapy, 31 out of 955 patients (3%) treated with Revolade experienced a TEE and 5 out of 484 patients (1%) in the placebo group experienced TEEs. Portal vein thrombosis was the most common TEE in both treatment groups (1% in patients treated with Revolade versus <1% for placebo). No specific temporal relationship between start of treatment and occurrence of TEE was observed. The majority of TEEs resolved and did not lead to the discontinuation of antiviral therapy.

In a controlled study in thrombocytopenic patients with chronic liver disease (n=288, safety population) undergoing elective invasive procedures, the risk of portal vein thrombosis was increased in patients treated with 75 mg Revolade once daily for 14 days. Six of 143 (4%) adult patients with chronic liver disease receiving Revolade experienced TEEs (all of the portal venous system) and two out of 145 (1%) patients in the placebo group experienced TEEs (one in the portal venous system and one myocardial infarction). Five Revolade-treated patients with a TEE experienced the event within 14 days of completing Revolade dosing and at a platelet count above 200,000/microL.

Revolade is not indicated for the treatment of thrombocytopenia in patients with chronic liver disease in preparation for invasive procedures.

**Bleeding following discontinuation of Revolade:**

Following discontinuation of Revolade in the ITP and HCV settings, platelet counts returned to baseline levels within 2 weeks in the majority of patients (see section CLINICAL STUDIES), which increases the bleeding risk and, in some cases may lead to bleeding. Platelet counts must be monitored weekly for 4 weeks following discontinuation of Revolade.

**Bone Marrow Reticulin Formation and Risk of Bone Marrow Fibrosis:**

Thrombopoietin (TPO) receptor agonists, including eltrombopag, may increase the risk for development or progression of reticulin fibers within the bone marrow.

Prior to initiation of Revolade, examine the peripheral blood smear closely to establish a baseline level of cellular morphologic abnormalities. Following identification of a stable dose of Revolade, perform complete blood count (CBC) with white blood cell count (WBC) differential monthly. If immature or dysplastic cells are observed, examine peripheral blood smears for new or worsening morphological abnormalities (e.g., teardrop and nucleated red blood cells, immature white blood cells) or cytopenia(s). If the patient develops new or worsening morphological abnormalities or cytopenia(s), discontinue treatment with Revolade and consider a bone marrow biopsy, including staining for fibrosis.

**Malignancies and progression of malignancies:**

There is a theoretical concern that thrombopoietin-receptor (TPO-R) agonists may stimulate the progression of existing hematological malignances such as MDS. The effectiveness and safety of Revolade have not been established for the treatment of thrombocytopenia due to MDS. Revolade should not be used outside of clinical studies for the treatment of thrombocytopenia due to MDS.

A randomized, double-blind, placebo-controlled, multicenter study in patients with International Prognostic Scoring System (IPSS) intermediate-1, intermediate-2 or high risk MDS with thrombocytopenia, receiving azacitidine in combination with either Revolade or placebo, was terminated due to futility and increased MDS progression, including to AML. A total of 356 patients (179 on Revolade, 177 on placebo) were randomized 1:1 and stratified by the International Prognostic Scoring System (IPSS): intermediate-1 (n=64 [36%]), intermediate-2 (n=79 [44%]), high-risk (n=36 [20%]) in the Revolade arm versus intermediate-1 (n=65 [37%]), intermediate-2 (n=79 [45%]), high-risk (n=33 [19%]) in the placebo arm. Patients were treated with either Revolade, at a starting dose of 200 mg once daily, up to a maximum of 300 mg once daily, or placebo in combination with azacitidine for at least six cycles. Based on central review assessment, there were 76 (42%) and 67 (38%) progression-free survival events, in the Revolade group and the placebo group, respectively. Twenty-one (12%) and 10 (6%) patients progressed to AML by central review assessment in the Revolade group and the placebo group, respectively. In the final analysis, overall survival favored the placebo arm: a total of 57 (32%) patients died on the Revolade arm versus 51 (29%) patients in the placebo arm.

### Cataracts:

Cataracts were observed in toxicology studies of eltrombopag in rodents (see section NON-CLINICAL SAFETY DATA).

In the two controlled Phase III studies in thrombocytopenic patients with HCV receiving interferon-based therapy (n=1,439), progression of pre-existing baseline cataract(s) or incident cataracts was reported in 8% of the Revolade group and 5% of the placebo group.

Routine monitoring of patients for cataracts is recommended.

### Interference with serological testing:

Eltrombopag is highly colored and has the potential to interfere with some laboratory tests. Serum discoloration and interference with total bilirubin and creatinine testing have been reported in patients taking Revolade. If the laboratory results and clinical observations are inconsistent, evaluation of contemporaneous aminotransferase values may help in determining the validity of low total bilirubin levels in the presence of clinical jaundice and blood urea should be evaluated in the event of an unexpectedly high serum creatinine. Re-testing using another method may also help in determining the validity of the result.

## ADVERSE DRUG REACTIONS

### Summary of the safety profile

**Immune thrombocytopenia in adult patients**

The safety of Revolade was assessed in adult patients (N=763) with previously treated ITP using data from pooled double-blind, placebo-controlled studies TRA100773A and B, TRA102537 (RAISE), and TRA113765 in which patients were exposed to Revolade (N=403) and to placebo (N=179), in addition to data from completed open label studies (N=360) TRA108057 (REPEAT), TRA105325 (EXTEND), and TRA112940 (see section CLINICAL

STUDIES). Patients received study medication for up to 8 years (in EXTEND). Adverse drug reactions for the adult ITP study population (N=763) are shown in Table 7.

The most common adverse drug reactions (≥10%) for Revolade were diarrhoea, nausea, increased alanine aminotransferase and back pain.

### Immune thrombocytopenia in pediatric patients

The safety of Revolade was assessed in pediatric patients (aged 1 to 17 years) with previously treated ITP using the all-treated population from two studies (N=171) (see section CLINICAL STUDIES). PETIT2 (TRA115450) was a two-part, double-blind and open-label, randomized, placebo-controlled study. Patients were randomized 2:1 and received Revolade (n=63) or placebo (n=29) for up to 13 weeks in the randomized period of the study. PETIT (TRA108062) was a three-part, staggered cohort, open-label and double-blind, randomized, placebo-controlled study. Patients were randomized 2:1 and received Revolade (n=44) or placebo (n=21) for up to 7 weeks. Adverse drug reactions in the adult ITP study population (Table 7) may also occur in the pediatric ITP population. Additional adverse drug reactions occurring in the pediatric ITP study population (N=171) are shown in Table 8.

The most common additional adverse drug reactions (≥10%) for Revolade were upper respiratory tract infection, pyrexia, abdominal pain, nasopharyngitis and cough.

### Thrombocytopenia with HCV infection in adult patients

The safety of Revolade was assessed in adult patients treated with Revolade using two controlled studies, including data from patients who initially received Revolade in the pre-antiviral treatment phase and were later randomized to the placebo arm (N=1,520) (see section CLINICAL STUDIES). ENABLE 1 (TPL103922; n=716, 715 treated with Revolade) and ENABLE 2 (TPL108390; n=805) were randomized, double-blind, placebo-controlled, multicenter studies to assess the efficacy and safety of Revolade in thrombocytopenic patients with HCV infection who were otherwise eligible to initiate antiviral therapy. In the HCV studies, the safety population consisted of all randomized patients who received double-blind study drug during Part 2 of ENABLE 1 (Revolade treatment n=449, placebo treatment n=232) and ENABLE 2 (Revolade treatment n=506, placebo treatment n=252). Patients were analyzed according to the treatment received (total safety double-blind population, Revolade n=955 and placebo n=484). Adverse drug reactions for the HCV study population (N=1,520) are shown in Table 9.

The most common adverse drug reactions (≥10%) for Revolade were anemia, pyrexia, fatigue, headache, nausea, influenza like illness, diarrhoea, decreased appetite, asthenia, pruritus, cough, chills, and myalgia.

### Definitive immunosuppressive therapy-naïve severe aplastic anemia in adult and pediatric patients

The safety of Revolade administered in combination with horse antithymocyte globulin (h-ATG) and cyclosporine to patients with severe aplastic anemia who had not received prior definitive immunosuppressive therapy (i.e., ATG therapy, alemtuzumab, or high dose cyclophosphamide) was evaluated in a single-arm, sequential cohort study (see section CLINICAL STUDIES). A total of 154 patients were enrolled and 153 were dosed in this study, of which 92 patients were enrolled to the cohort where Revolade, h-ATG, and cyclosporine

were initiated concurrently at the recommended dose and schedule (Cohort 3 regimen): Revolade up to 150 mg once daily on Day 1 to Month 6 (D1M6) in combination with h-ATG on Days 1 to 4 and cyclosporine for 6 months, followed by low dose of cyclosporine (maintenance dose) for an additional 18 months for patients who achieved a haematologic response at 6 months. The median duration of exposure to Revolade in this cohort was 183 days with 83.7% of patients exposed for >12 weeks. Adverse drug reactions for the first-line SAA study population (N=92) are shown in Table 10.

The most common adverse drug reactions (≥10%) for Revolade were alanine aminotransferase increased, aspartate aminotransferase increased and blood bilirubin increased (including ocular icterus).

### Refractory severe aplastic anemia in adult patients

The safety of Revolade in refractory severe aplastic anemia was assessed in a single-arm, open-label study (N=43) in which 11 patients (26%) were treated for >6 months and 7 patients (16%) were treated for >1 year (see section CLINICAL STUDIES). Adverse drug reactions for the refractory SAA study population (N=43) are shown in Table 11.

The most common adverse drug reactions (≥10%) for Revolade were nausea, fatigue, cough, headache, diarrhoea, pain in extremity, dizziness, oropharyngeal pain, pyrexia, rhinorrhoea, abdominal pain, transaminases increased, arthralgia and muscle spasms.

Most adverse drug reactions associated with Revolade in ITP, HCV and SAA were mild to moderate in severity, early in onset and rarely treatment-limiting.

### Tabulated summary of reactions from clinical trials

Adverse drug reactions from clinical studies are listed below by MedDRA body system organ class and by frequency. Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first. The corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common ($\geq 1/10$); common ($\geq 1/100$ to $<1/10$); uncommon ($\geq 1/1,000$ to $<1/100$); rare ($\geq 1/10,000$ to $<1/1,000$); very rare ($<1/10,000$).

**Table 7      Adverse drug reactions in the adult ITP study population (N=763)**

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| **Infections and infestations** | | |
| Pharyngitis | 4.2 | common |
| **Eye disorders** | | |
| Cataract | 5.0 | common |
| **Vascular disorders** | | |
| Thromboembolic events | 5.5 | common |
| Thrombotic microangiopathy with acute renal failure | 1.2 | common |
| **Gastrointestinal disorders** | | |
| Diarrhoea | 12.6 | very common |
| Nausea | 11.1 | very common |

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| Vomiting | 7.3 | common |
| Dry mouth | 0.9 | uncommon |
| **Hepatobiliary disorders** | | |
| Increased alanine aminotransferase | 10.5 | very common |
| Increased aspartate aminotransferase | 9.7 | common |
| Hyperbilirubinaemia | 1.8 | common |
| Drug-induced liver injury | 0.1 | uncommon |
| **Skin and subcutaneous tissue disorders** | | |
| Rash | 7.5 | common |
| Alopecia | 3.0 | common |
| **Musculoskeletal and connective tissue disorders** | | |
| Back pain | 10.5 | very common |
| Myalgia | 4.2 | common |
| Musculoskeletal pain (incl. musculoskeletal chest pain) | 3.7 | common |

**Table 8          Additional adverse drug reactions in the pediatric ITP study population aged 1 to 17 years (N=171)**

These additional adverse drug reactions were observed in the pediatric ITP study population.

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| **Infections and infestations** | | |
| Upper respiratory tract infection | 25.7 | very common |
| Nasopharyngitis | 15.8 | very common |
| **Respiratory, thoracic and mediastinal disorders** | | |
| Cough | 13.5 | very common |
| Oropharyngeal pain | 9.4 | common |
| Rhinorrhoea | 4.1 | common |
| **Gastrointestinal disorders** | | |
| Abdominal pain | 17.5 | very common |
| Toothache | 5.8 | common |
| **General disorders and administration site conditions** | | |
| Pyrexia | 18.1 | very common |

**Table 9        Adverse drug reactions in the HCV study population (N=1,520)**

Revolade in combination with interferon anti-viral therapy.

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| **Blood and lymphatic system disorders** | | |
| Anemia | 30.6 | very common |
| **Metabolism and nutrition disorders** | | |
| Decreased appetite | 14.4 | very common |
| **Nervous system disorders** | | |
| Headache | 22.2 | very common |
| **Eye disorders** | | |
| Cataract | 2.4 | common |
| **Vascular disorders** | | |
| Thromboembolic events (incl. portal vein thrombosis) | 2.1 | common |
| **Respiratory, thoracic and mediastinal disorders** | | |
| Cough | 11.8 | very common |
| **Gastrointestinal disorders** | | |
| Nausea | 17.7 | very common |
| Diarrhoea | 15.5 | very common |
| **Hepatobiliary disorders** | | |
| Hyperbilirubinaemia | 6.4 | common |
| Drug-induced liver injury | 2.1 | common |
| Hepatic failure | 0.7 | uncommon |
| **Skin and subcutaneous tissue disorders** | | |
| Pruritus | 12.2 | very common |
| Rash | 7.3 | common |
| Alopecia | 7.0 | common |
| **Musculoskeletal and connective tissue disorders** | | |
| Myalgia | 11.2 | very common |
| **General disorders and administration site conditions** | | |
| Pyrexia | 26.1 | very common |
| Fatigue | 25.0 | very common |
| Influenza like illness | 16.4 | very common |
| Asthenia | 13.2 | very common |
| Chills | 11.8 | very common |
| Oedema | 1.3 | common |

**Table 10          Adverse drug reactions in the definitive immunosuppressive therapy-naïve SAA (first-line SAA) study population (N=92)**

Revolade in combination with standard immunosuppressive therapy.

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| **Gastrointestinal disorders** | | |
| Nausea | 4.3 | common |
| Diarrhoea | 3.3 | common |
| Abdominal pain | 3.3 | common |
| **Skin and subcutaneous tissue disorders** | | |
| Rash | 7.6 | common |
| Skin discoloration including hyperpigmentation | 5.4 | common |
| **Investigations** | | |
| Alanine aminotransferase increased | 29.3 | very common |
| Aspartate aminotransferase increased | 17.4 | very common |
| Blood bilirubin increased (including ocular icterus) | 17.4 | very common |

New or worsening liver function laboratory abnormalities (CTCAE Grade 3 and Grade 4) in the Revolade D1-M6 cohort were 15.2% and 2.2% for AST, 26.4% and 4.3% for ALT, and 12.1% and 1.1% for bilirubin, respectively.

*Pediatric patients*

The safety assessment of Revolade in definitive immunosuppressive therapy-naïve pediatric SAA patients 2 to 17 years old is based on 37 patients enrolled in the single-arm, sequential cohort study: 2 patients aged 2 to 5 years, 12 patients aged 6 to 11 years, and 23 patients aged 12 to 17 years (see section CLINICAL STUDIES). The safety profile in pediatric patients was consistent with the safety profile observed in the overall population.

*Cytogenetic abnormalities*

In the single-arm study in patients with definitive immunosuppressive therapy-naïve SAA, patients had bone marrow aspirates evaluated for cytogenetic abnormalities. In the entire study across all cohorts, clonal cytogenetic evolution occurred in 15 out of 153 patients (10%). Of the 15 patients who experienced a cytogenetic abnormality, 7 patients had the loss of chromosome 7, six of which occurred within 6.1 months; 4 patients had chromosomal aberrations which were of unclear significance; 3 patients had a deletion of chromosome 13, which is considered a good prognostic factor in aplastic anemia; and 1 patient had a follow-up bone marrow assessment at 5 years with features of dysplasia with hypercellularity concerning for potential development of MDS. In the Revolade D1-M6 cohort, 7 patients had a new cytogenetic abnormality reported of which 4 had the loss of chromosome 7 occurring within 6.1 months.

It is unclear whether these findings occurred due to the underlying disease, the immunosuppressive therapy, and/or treatment with Revolade.

**Table 11          Adverse drug reactions in the refractory SAA study population (N=43)**

| Adverse drug reactions | Revolade % | Frequency category |
|---|---|---|
| **Nervous system disorders** | | |
| Headache | 20.9 | very common |
| Dizziness | 14.0 | very common |
| **Eye disorders** | | |
| Cataract | 2.3 | common |
| **Respiratory, thoracic and mediastinal disorders** | | |
| Cough | 23.3 | very common |
| Oropharyngeal pain | 14.0 | very common |
| Rhinorrhoea | 11.6 | very common |
| **Gastrointestinal disorders** | | |
| Nausea | 32.6 | very common |
| Diarrhoea | 20.9 | very common |
| Abdominal pain | 11.6 | very common |
| **Hepatobiliary disorders** | | |
| Transaminases increased | 11.6 | very common |
| Hyperbilirubinaemia | 4.7 | common |
| **Skin and subcutaneous tissue disorders** | | |
| Rash | 7.0 | common |
| **Musculoskeletal and connective tissue disorders** | | |
| Pain in extremity | 18.6 | very common |
| Arthralgia | 11.6 | very common |
| Muscle spasms | 11.6 | very common |
| **General disorders and administration site conditions** | | |
| Fatigue | 30.2 | very common |
| Pyrexia | 14.0 | very common |

In the single-arm, open-label study in refractory SAA, patients had bone marrow aspirates evaluated for cytogenetic abnormalities. Eight patients had a new cytogenetic abnormality reported, including 5 patients who had changes in chromosome 7.

## Adverse drug reactions from spontaneous reports and literature cases (frequency not known)

The following adverse drug reactions have been reported during post-approval use of Revolade. These include spontaneous case reports as well as serious adverse events from registries, investigator sponsored studies, clinical pharmacology studies and exploratory studies in unapproved indications. Because they are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency, which is therefore categorized as not known. Adverse drug reactions are listed according to system organ classes in MedDRA.

**Table 12          Adverse drug reactions identified during post-approval use**

| **Skin and subcutaneous tissue disorders** |
| --- |
| Skin discoloration* |

*In patients taking Revolade reversible skin discoloration including hyperpigmentation and skin yellowing was observed at Revolade doses higher than 100 mg per day. Skin discoloration was particularly observed in patients taking Revolade for indications that require administration of high doses of eltrombopag including severe aplastic anemia.*

## INTERACTIONS

### Effects of other drugs on Revolade

**Cyclosporine:**

A decrease in eltrombopag exposure was observed with co-administration of 200 mg and 600 mg cyclosporine (a BCRP inhibitor). Administration of a single dose of Revolade 50 mg with 200 mg cyclosporine) decreased the Cmax and the AUCinf of eltrombopag by 25% (90% CI: 15%, 35%) and 18% (90% CI: 8%, 28%), respectively. The co-administration of 600 mg cyclosporine decreased the Cmax and the AUCinf of eltrombopag by 39% (90% CI: 30%, 47%) and 24% (90% CI: 14%, 32%), respectively. This decrease in exposure is not considered clinically meaningful. Revolade dose adjustment is permitted during the course of the treatment based on the patient's platelet count (see section DOSAGE REGIMEN AND ADMINISTRATION). Platelet count should be monitored at least weekly for 2 to 3 weeks when Revolade is co-administered with cyclosporine. Revolade dose may need to be increased based on these platelet counts.

**Polyvalent Cations (Chelation):**

Eltrombopag chelates with polyvalent cations such as aluminium, calcium, iron, magnesium, selenium, and zinc (see section CLINICAL PHARMACOLOGY). Administration of a single dose of Revolade 75 mg with a polyvalent cation-containing antacid (1524 mg aluminium hydroxide and 1425 mg magnesium carbonate) decreased plasma eltrombopag AUCinf by 70% (90% CI: 64%, 76%) and Cmax by 70% (90% CI: 62%, 76%) (see section DOSAGE REGIMEN AND ADMINISTRATION).). Revolade should be taken at least two hours before or four hours after any products such as antacids, dairy products, or mineral supplements containing polyvalent cations to avoid significant reduction in eltrombopag absorption (see section DOSAGE REGIMEN AND ADMINISTRATION, METHOD OF ADMINISTRATION).

**Lopinavir/ritonavir:**

Co-administration of Revolade with lopinavir/ritonavir may cause a decrease in the concentration of eltrombopag. A study in 40 healthy volunteers showed that the co-administration of a single 100 mg dose of Revolade with repeat dose lopinavir/ritonavir 400 /100 mg twice daily resulted in a reduction in eltrombopag plasma AUCinf by 17% (90% CI: 6.6%, 26.6%).

Therefore, caution should be used when co-administration of Revolade with lopinavir/ritonavir takes place. Platelet count should be monitored at least weekly for 2 to 3 weeks in order to

ensure appropriate medical management of the dose of Revolade when lopinavir/ritonavir therapy is initiated or discontinued.

**HCV protease inhibitors:**

Co-administration of repeat doses of boceprevir 800 mg every 8 hours or telaprevir 750 mg every 8 hours with a single dose of Revolade 200 mg did not alter plasma eltrombopag exposure to a clinically significant extent.

## Effects of Revolade on other drugs

**Rosuvastatin:**

Administration of Revolade 75 mg once daily for 5 days with a single 10 mg dose of the OATP1B1 and BCRP substrate rosuvastatin to 39 healthy adults increased plasma rosuvastatin $C_{max}$ 103% (90% CI: 82%, 126%) and $AUC_{inf}$ 55% (90% CI: 42%, 69%).

When co-administered with Revolade, a reduced dose of rosuvastatin should be considered and careful monitoring should be undertaken. In clinical studies with Revolade, a dose reduction of rosuvastatin by 50% was recommended for co-administration of rosuvastatin and Revolade. Concomitant administration of Revolade and other OATP1B1 and BCRP substrates should be undertaken with caution.

**Cytochrome P450 substrates:**

Administration of Revolade 75 mg once daily for 7 days to 24 healthy males did not inhibit or induce the metabolism of probe substrates for 1A2 (caffeine), 2C19 (omeprazole), 2C9 (flurbiprofen), or 3A4 (midazolam) in humans. No clinically significant interactions are expected when eltrombopag and CYP450 substrates, inducers or inhibitors are co-administered.

**HCV Protease inhibitors:**

Co-administration of a single dose of Revolade 200 mg with telaprevir 750 mg every 8 hours did not alter plasma telaprevir exposure. Co-administration of a single dose of Revolade 200 mg with boceprevir 800 mg every 8 hours did not alter plasma boceprevir $AUC_{tau}$, increased $C_{max}$ by 19%, and decreased $C_{min}$ by 32%. Dose adjustment is not required when Revolade is co-administered with either telaprevir or boceprevir.

## Drug-food/-drink interactions

Administration of a single 50 mg-dose of Revolade tablet with a standard high-calorie, high-fat breakfast that included dairy products reduced plasma eltrombopag $AUC_{inf}$ by 59% (90% CI: 54%, 64%) and $C_{max}$ by 65% (90% CI: 59%, 70%). Administration of a single 25-mg dose of Revolade powder for oral suspension with a high-calcium, moderate fat and calorie meal reduced plasma eltrombopag $AUC_{inf}$ by 75% (90% CI: 71%, 88%) and $C_{max}$ by 79% (90% CI: 76%, 82%). Administration of a single 25-mg dose of Revolade powder for oral suspension 2 hours before a high-calcium meal attenuated the effect, where plasma eltrombopag $AUC_{inf}$ was decreased by 20% (90% CI: 9%, 29%) and $C_{max}$ by 14% (90% CI: 2%, 25%). Administration of a single 25-mg dose of Revolade powder for oral suspension 2 hours after the high-calcium meal reduced plasma eltrombopag $AUC_{inf}$ by 47% (90% CI: 40%, 53%) and $C_{max}$ by 48% (90% CI: 40%, 54%). Food low in calcium (<50 mg calcium) including fruit,

lean ham, beef and unfortified (no added calcium, magnesium, iron) fruit juice, unfortified soy milk, and unfortified grain did not significantly impact plasma eltrombopag exposure, regardless of calorie and fat content (see section DOSAGE REGIMEN AND ADMINISTRATION, METHOD OF ADMINISTRATION).

## EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

There have been no studies to investigate the effect of eltrombopag on driving performance or the ability to operate machinery. A detrimental effect on such activities would not be anticipated from the pharmacology of eltrombopag. The clinical status of the patient and the adverse event profile of eltrombopag should be borne in mind when considering the patient's ability to perform tasks that require judgement, motor and cognitive skills.

## PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

### Pregnancy

### Risk summary

There are no adequate and well-controlled studies of Revolade in pregnant women to inform a drug-associated risk. In animal developmental and reproductive toxicology studies, oral administration of eltrombopag to pregnant rats and rabbits throughout organogenesis resulted in developmental toxicity in rats (see Animal data). The effect of eltrombopag on human pregnancy is unknown. Pregnant women or women of childbearing potential should be advised of the potential risk of Revolade to a fetus. Revolade should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.

**Animal data**

In embryo-fetal developmental toxicity studies in rats and rabbits, oral eltrombopag was administered to pregnant animals during organogenesis. In rats, a maternally toxic dose of 60 mg/kg/day (6 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 3 times the human clinical exposure based on AUC in patients with chronic hepatitis C at 100 mg/day) resulted in decreased fetal weights and a slight increase in the incidence of the fetal variation, cervical rib. No evidence of major structural malformations was observed. In rabbits, there was no evidence of embryo-fetal toxicity or teratogenicity up to 150 mg/kg/day (0.5 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 0.3 times the human clinical exposure based on AUC in patients with chronic hepatitis C at 100 mg/day).

In a pre-and postnatal developmental toxicity study in pregnant rats, oral eltrombopag was administered from gestation day 6 through lactation Day 20. No adverse effects on maternal reproductive function or on the development of the offspring were observed at doses up to 20 mg/kg/day (2 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and similar to the human clinical exposure based on AUC in patients with chronic hepatitis C at 100 mg/day). Eltrombopag was detected in the plasma of offspring. The plasma concentrations in pups increased with dose following administration of drug to the F0 dams.

### Lactation

### Risk summary

There is no information regarding the presence of eltrombopag or its metabolites in human milk, or their effects on the breastfed infant, or on milk production. However, eltrombopag was detected in the pups of lactating rats 10 days postpartum suggesting the potential for transfer during lactation. A decision must be made whether to discontinue breastfeeding or to continue/abstain from Revolade therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.

### Females and males of reproductive potential

### Contraception

Based on animal reproduction studies, Revolade can cause fetal harm when administered to a pregnant woman (see section PREGNANCY). Sexually-active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) when using Revolade during treatment and for at least 7 days after stopping treatment with Revolade.

### Infertility

There is no effect of Revolade on fertility based on animal studies (see section NON-CLINICAL SAFETY DATA). Eltrombopag did not affect female or male fertility in rats at doses 2 and 3 times respectively the human clinical exposure based on AUC in patients with ITP at 75 mg/day and in patients with chronic Hepatitis C at 100 mg/day (see section NON-CLINICAL SAFETY DATA).

## OVERDOSAGE

In the clinical studies, there was one report of overdose where the patient ingested 5,000 mg of Revolade. Reported adverse events included mild rash, transient bradycardia, fatigue and elevated transaminases. Liver enzymes measured between Days 2 and 18 after ingestion peaked at 1.6-fold ULN in AST, 3.9-fold ULN in ALT, and 2.4-fold ULN in total bilirubin. The platelet counts were 672,000/microL on day 18 after ingestion and the maximum platelet count was 929,000/microL. All events resolved without sequelae following treatment.

In the event of overdose, platelet counts may increase excessively and result in thrombotic/thromboembolic complications. In case of an overdose, oral administration of a metal cation-containing preparation, such as calcium, aluminium, or magnesium preparations to chelate eltrombopag and thus limit absorption should be considered. Platelet counts should be closely monitored. Treatment with Revolade should be reinitiated in accordance with dosing and administration recommendations (see section DOSAGE REGIMEN AND ADMINISTRATION).

Because eltrombopag is not significantly renally excreted and is highly bound to plasma proteins, hemodialysis would not be expected to be an effective method to enhance the elimination of eltrombopag.

## CLINICAL PHARMACOLOGY

### Mechanism of action (MOA)

Thrombopoietin (TPO) is the main cytokine involved in regulation of megakaryopoiesis and platelet production, and is the endogenous ligand for the TPO-receptor. Eltrombopag interacts with the transmembrane domain of the human TPO-receptor and initiates signaling cascades similar but not identical to that of endogenous TPO, inducing proliferation and differentiation of megakaryocytes and bone marrow progenitor cells.

### Pharmacodynamics (PD)

Eltrombopag differs from TPO with respect to the effects on platelet aggregation. Unlike TPO, eltrombopag treatment of normal human platelets does not enhance adenosine diphosphate (ADP)-induced aggregation or induce P-selectin expression. Eltrombopag does not antagonize platelet aggregation induced by ADP or collagen.

### Pharmacokinetics (PK)

The pharmacokinetic parameters of eltrombopag after administration of Revolade to adult patients with ITP are shown in Table 13.

**Table 13      Steady-state plasma eltrombopag pharmacokinetic parameters in adults with immune thrombocytopenia**

| Revolade dose (once daily) | N | Cmax (microg/mL) | AUCtau (microg.h/mL) |
|---|---|---|---|
| 50 mg | 34 | 8.01 (6.73, 9.53) | 108 (88, 134) |
| 75 mg | 26 | 12.7 (11.0, 14.5) | 168 (143, 198) |

Data presented as geometric mean (95 % CI). AUCtau and Cmax based on population PK post-hoc estimates.

Plasma eltrombopag concentration-time data collected in 590 patients with HCV enrolled in Phase III studies TPL103922/ENABLE 1 and TPL108390/ENABLE 2 were combined with data from patients with HCV enrolled in the Phase II study TPL102357 and healthy adults in a population pharmacokinetic analysis. Plasma eltrombopag Cmax and AUCtau estimates for patients with HCV enrolled in the Phase III studies are presented for each dose studied in Table 14. A higher eltrombopag exposure was observed in patients with HCV at a given Revolade dose.

**Table 14      Steady-state plasma eltrombopag pharmacokinetic parameters in adults with chronic HCV**

| Revolade dose (once daily) | N | Cmax (microg/mL) | AUCtau (microg.h/mL) |
|---|---|---|---|
| 25 mg | 330 | 6.40 (5.97, 6.86) | 118 (109, 128) |
| 50 mg | 119 | 9.08 (7.96, 10.35) | 166 (143, 192) |
| 75 mg | 45 | 16.71 (14.26, 19.58) | 301 (250, 363) |
| 100 mg | 96 | 19.19 (16.81, 21.91) | 354 (304, 411) |

Data presented as geometric mean (95%CI). AUCtau and Cmax based on population PK post-hoc estimates at the highest dose in the data for each patient.

The pharmacokinetic parameters of eltrombopag after administration of Revolade 150 mg to 45 patients with definitive immunosuppressive therapy-naïve severe aplastic anemia are shown in Table 15.

**Table 15          Steady-state plasma eltrombopag pharmacokinetic parameters in patients with definitive immunosuppressive therapy-naïve severe aplastic anemia**

| Revolade dose (once daily) | N | Cmax(microg/mL) | AUCtau(microg.h/mL) |
|---|---|---|---|
| 150 mg | 45 | 40.1 (44.9%) | 772 (47.2%) |
| *Data presented as geometric mean (geometric mean coefficient of variation).* | | | |

## Absorption

Eltrombopag is absorbed with a peak concentration occurring 2 to 6 hours after oral administration. Administration of Revolade concomitantly with antacids and other products containing polyvalent cations such as dairy products and mineral supplements significantly reduces eltrombopag exposure (see section INTERACTIONS). In a relative bioavailability study in adults, Revolade powder for oral suspension delivered a 22% higher plasma AUCinf than the film-coated tablet formulation. The absolute oral bioavailability of eltrombopag after administration to humans has not been established. Based on urinary excretion and metabolites eliminated in feces, the oral absorption of drug-related material following administration of a single 75 mg Revolade solution dose was estimated to be at least 52%.

## Distribution

Eltrombopag is highly bound to human plasma proteins (>99.9%). Eltrombopag is a substrate for BCRP, but is not a substrate for P-glycoprotein or OATP1B1.

## Biotransformation/metabolism

Eltrombopag is primarily metabolized through cleavage, oxidation and conjugation with glucuronic acid, glutathione, or cysteine. In a human radiolabel study, eltrombopag accounted for approximately 64% of plasma radiocarbon AUCinf. Minor metabolites, each accounting for <10% of the plasma radioactivity, arising from glucuronidation and oxidation were also detected. Based on a human study with radiolabel eltrombopag, it is estimated that approximately 20% of a dose is metabolized by oxidation.

## Elimination

Absorbed eltrombopag is extensively metabolized. The predominant route of eltrombopag excretion is via feces (59%) with 31% of the dose found in the urine as metabolites. Unchanged parent compound (eltrombopag) is not detected in urine. Unchanged eltrombopag excreted in feces accounts for approximately 20% of the dose. The plasma elimination half-life of eltrombopag is approximately 21-32 hours.

### *In vitro* evaluation of drug interaction potential

Based on a human study with radiolabeled eltrombopag, glucuronidation plays a minor role in the metabolism of eltrombopag. Human liver microsome studies identified UGT1A1 and UGT1A3 as the enzymes responsible for eltrombopag glucuronidation. Eltrombopag was an inhibitor of a number of UGT enzymes *in vitro*. Clinically significant drug interactions involving glucuronidation are not anticipated due to limited contribution of individual UGT enzymes in the glucuronidation of eltrombopag and potential co-medications.

Based on a human study with radiolabeled eltrombopag, approximately 21% of an eltrombopag dose could undergo oxidative metabolism. Human liver microsome studies identified CYP1A2 and CYP2C8 as the enzymes responsible for eltrombopag oxidation. In studies utilizing human liver microsomes, eltrombopag (up to 100 microM) showed no *in vitro* inhibition of the CYP450 enzymes 1A2, 2A6, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11 and was an inhibitor of CYP2C8 and CYP2C9 as measured using paclitaxel and diclofenac as the probe substrates, with IC50 values of 24.8 microM (11 microgram/mL) and 20.2 microM (8.9 microgram/mL), respectively.

*In vitro* studies demonstrate that eltrombopag is an inhibitor of the OATP1B1 transporter, with an $IC_{50}$ value of 2.7 microM (1.2 microg/mL) and an inhibitor of the BCRP transporter, with an $IC_{50}$ value of 2.7 microM (1.2 microg/mL).

*In vitro* studies identified CYP1A2 and CYP2C8 as the isoenzymes responsible for oxidative metabolism, uridine diphosphoglucuronyl transferase UGT1A1 and UGT1A3 as the isozymes responsible for glucuronidation, and that bacteria in the lower gastrointestinal tract may be responsible for the cleavage pathways.

*In vitro* studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, but is an inhibitor of this transporter ($IC_{50}$ value of 2.7 microM (1.2 microgram/mL). In vitro studies also demonstrated that eltrombopag is a breast cancer resistance protein (BCRP) substrate and inhibitor ($IC_{50}$ value of 2.7 microM (1.2 microgram/mL)).

## Special populations

## Pediatric population (aged 1 to 17 years)

The pharmacokinetics of eltrombopag have been evaluated in 168 pediatric ITP patients dosed once daily in two studies, TRA108062/PETIT and TRA115450/PETIT2. Plasma eltrombopag apparent clearance following oral administration (CL/F) increased with increasing body weight. Approximately 30% lower plasma eltrombopag CL/F was observed in patients of East-/Southeast-Asian ancestry and 20% lower CL/F was observed in female patients. The bioavailability of the powder for oral suspension in pediatric patients was estimated as 29% lower than the film-coated tablet.

The pharmacokinetic parameters of eltrombopag in pediatric patients with ITP are shown in Table 16.

**Table 16**    **Steady-state plasma eltrombopag pharmacokinetic parameters in pediatric patients with ITP**

| Age | Cmax(microgram/mL) | AUCtau(microgram.hr/mL) |
|---|---|---|
| 12 to 17 years (n=62) | 6.80 (6.17, 7.50) | 103 (91.1, 116) |
| 6 to 11 years (n=68) | 10.3 (9.42, 11.2) | 153 (137, 170) |
| 1 to 5 years (n=38) | 11.6 (10.4, 12.9) | 162 (139, 187) |

Data presented as geometric mean (95%CI). AUCtau and Cmax based on population PK post-hoc estimates for a 50 mg once daily dose.

## Geriatric patients (60 years of age or above)

The age difference of eltrombopag pharmacokinetics was evaluated using population pharmacokinetic analysis in 28 healthy subjects and 635 patients with HCV ranging from 19 to 74 years old. Based on model estimates, elderly (>60 years) patients had approximately 36% higher plasma eltrombopag AUCtau as compared to younger patients.

## Gender

The influence of gender on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 111 healthy adults (14 females) and 88 patients with ITP (57 females). Based on estimates from the population pharmacokinetic analysis, female ITP patients had approximately 50% higher plasma eltrombopag AUCtau as compared to male ITP patients, without adjustment for body weight differences.

The influence of gender on eltrombopag pharmacokinetics was evaluated using a population pharmacokinetic analysis in 663 patients with HCV (260 females). Based on model estimates, female HCV patients had approximately 41% higher plasma eltrombopag AUCtau as compared to male patients.

## Race/Ethnicity

ITP: The influence of East-Asian ethnicity on the pharmacokinetics of eltrombopag was evaluated using a population PK analysis in 111 healthy adults (31 East-Asians) and 88 patients with ITP (18 East-Asians). Based on estimates from the population pharmacokinetic analysis, East-Asian ITP patients had approximately 87% higher plasma eltrombopag AUCtau values as compared to non-East-Asian patients who were predominantly Caucasian, without adjustment for body weight differences (see section DOSAGE REGIMEN AND ADMINISTRATION).

HCV-associated thrombocytopenia: The influence of East-/Southeast-Asian ethnicity on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 663 patients with HCV (214 East-/Southeast-Asian). Based on estimates from the population pharmacokinetic analysis, East-/Southeast-Asian patients had similar pharmacokinetics of eltrombopag. On average, East-/Southeast-Asian patients had approximately 55% higher plasma eltrombopag AUCtau values as compared to patients of other races who were predominantly Caucasian (see section DOSAGE REGIMEN AND ADMINISTRATION).

**Renal impairment**

The pharmacokinetics of eltrombopag have been studied after administration of Revolade to adult patients with renal impairment. Following administration of a single 50 mg-dose, the AUCinf of eltrombopag was decreased by 32% (90% CI: 63%, 26%) in patients with mild renal impairment, 36% (90% CI: 66%, 19%) in patients with moderate renal impairment, and 60% (90% CI: 18%, 80%) in patients with severe renal impairment compared with healthy volunteers. There was a trend for reduced plasma eltrombopag exposure in patients with renal impairment, but there was substantial variability and significant overlap in exposures between patients with renal impairment and healthy volunteers.

**Hepatic impairment**

The pharmacokinetics of eltrombopag have been studied after administration of Revolade to adult patients with liver cirrhosis (hepatic impairment). Following the administration of a single 50-mg dose, the AUCinf of eltrombopag was increased by 41% (90% CI: 13%, 128%) in patients with mild hepatic impairment, 93% (90% CI: 19%, 213%) in patients with moderate hepatic impairment, and 80% (90% CI: 11%, 192%) in patients with severe hepatic impairment compared with healthy volunteers. There was substantial variability and significant overlap in exposures between patients with hepatic impairment and healthy volunteers.

The influence of hepatic impairment on the pharmacokinetics of eltrombopag following repeat administration was evaluated using a population pharmacokinetic analysis in 28 healthy adults and 79 patients with chronic liver disease. Based on estimates from the population pharmacokinetic analysis, patients with liver cirrhosis (hepatic impairment) had higher plasma eltrombopag AUCtau values as compared to healthy volunteers, and AUCtau increased with increasing Child-Pugh score. Compared to healthy volunteers, patients with mild hepatic impairment had approximately 87% to 110% higher plasma eltrombopag AUCtau values and patients with moderate hepatic impairment had approximately 141% to 240% higher plasma eltrombopag AUCtau values.

A similar analysis was also conducted in 28 healthy adults and 635 patients with HCV. A majority of patients had Child Pugh score of 5-6. Based on estimates from the population pharmacokinetic analysis, patients with HCV had higher plasma eltrombopag AUCtau values as compared to healthy subjects, and AUCtau increased with increasing Child-Pugh score, HCV patients with mild hepatic impairment had approximately 100% to 144% higher plasma eltrombopag AUCtau compared with healthy subjects. For patients with HCV, Revolade should be initiated at a dose of 25 mg once daily (see section DOSAGE REGIMEN AND ADMINISTRATION, HEPATIC IMPAIRMENT).

## CLINICAL STUDIES

### Immune thrombocytopenia (ITP) studies

### Adults

The safety and efficacy of Revolade in adult patients with previously treated ITP have been demonstrated in two, randomized, double-blind, placebo-controlled studies (TRA102537

[RAISE] and TRA100773B) and two open label studies (TRA108057 [REPEAT] and TRA105325 [EXTEND]) The single-arm phase II study TAPER (CETB115J2411) evaluated the safety and efficacy of Revolade and its ability to induce sustained response after treatment discontinuation in 105 adult ITP patients who relapsed or failed to respond to first-line corticosteroid treatment.

## Double-blind placebo-controlled studies

### *TRA102537 (RAISE):*

In TRA102537, the primary efficacy endpoint was the odds of achieving a platelet count $\geq$50,000/microL and $\leq$400,000/microL, during the 6-month treatment period, for patients receiving Revolade relative to placebo. One hundred and ninety-seven patients were randomized 2:1 to Revolade (n=135) and to placebo (n=62). Stratification was based upon splenectomy status, use of ITP medication at baseline, and baseline platelet count. Patients received study medication for up to 6-months, during which time the dose of Revolade could be adjusted based on individual platelet counts. In addition, patients could have tapered off concomitant ITP medications and received rescue treatments according to local standard of care.

The odds of achieving a platelet count between 50,000/microL and 400,000/microL during the 6-month treatment period were 8 times higher for Revolade-treated patients than for placebo-treated patients (Odds Ratio (OR): 8.2 [99% CI: 3.59, 18.73] p= <0.001). Median platelet counts were maintained above 50,000/microL at all on-therapy visits starting at Day-15 in the Revolade group; in contrast, median platelet counts in the placebo group remained below 30,000/microL throughout the study.

At baseline, 77% of patients in the placebo group and 73% of patients in the Revolade group reported any bleeding (WHO Grades 1-4); clinically significant bleeding (WHO Grades 2-4) at baseline was reported in 28% and 22% of patients in the placebo and Revolade groups, respectively. The proportion of patients with any bleeding (Grades 1-4) and clinically significant bleeding (Grades 2-4) was reduced from baseline by approximately 50% throughout the 6 month treatment period in Revolade-treated patients. When compared to the placebo group, the odds of any bleeding (Grades 1-4) and the odds of clinically significant bleeding (Grades 2-4) were 76% and 65% lower in the Revolade-treated patients compared to the placebo-treated patients (p <0.001).

Revolade therapy allowed significantly more patients to reduce or discontinue baseline ITP therapies compared to placebo (59% vs. 32%; p <0.016).

Significantly fewer Revolade-treated patients required rescue treatment compared to placebo-treated patients (18% vs. 40%; p=0.001).

Four placebo and 14 Revolade patients had at least 1 hemostatic challenge (defined as an invasive diagnostic or surgical procedure) during the study. Fewer Revolade-treated patients (29%) required rescue treatment to manage their hemostatic challenge, compared to placebo-treated patients (50%).

In terms of improvements in health-related quality of life, statistically significant improvements from baseline were observed in the Revolade group in fatigue, including severity and impact

on thrombocytopenia-impacted daily activities and concerns (as measured by the vitality subscale of the SF36, the motivation and energy inventory, and the 6-item extract from the thrombocytopenia subscale of the FACIT-Th). Comparing the Revolade group to the placebo group, statistically significant improvements were observed with thrombocytopenia impacted activities and concerns specifically regarding motivation, energy and fatigue, as well as physical and emotional role and overall mental health. The odds of meaningful improvement in health-related quality of life while on therapy were significantly greater among patients treated with Revolade than placebo.

*TRA100773B*:

In TRA100773B, the primary efficacy endpoint was the proportion of responders, defined as patients who had an increase in platelet counts to ≥50,000/microL at Day 43 from a baseline platelet count <30,000/microL; patients who withdrew prematurely due to a platelet count >200,000/microL were considered responders, those discontinued for any other reason were considered non-responders irrespective of platelet count. A total of 114 patients with previously treated ITP were randomized 2:1, with 76 randomized to Revolade and 38 randomized to placebo.

Fifty-nine percent of patients on Revolade responded, compared to 16% of patients on placebo. The odds of responding were 9 times higher for Revolade-treated patients compared to placebo (OR: 9.6 [95% CI: 3.31, 27.86] p <0.001). At baseline, 61% of patients in the Revolade group and 66% of patients in the placebo group reported any bleeding (Grade 1-4). At Day 43, 39% of patients in the Revolade treatment group had bleeding compared with 60% in the placebo group. Analysis over the treatment period using a repeated measures model for binary data confirmed that a lower proportion of Revolade patients had bleeding (Grade 1-4) at any point in time over the course of their treatment (Day 8 up to Day 43) compared to patients in the placebo group (OR:0.49, (95% CI: 0.26, 0.89), p=0.021). Two placebo and one Revolade patient had at least one hemostatic challenge during the study.

In both RAISE and TRA100773B the response to Revolade relative to placebo was similar irrespective of ITP medication use, splenectomy status and baseline platelet count (≤15,000/microL, >15,000/microL) at randomization.

**Open label non-controlled studies**

*TRA108057 (REPEAT)*:

TRA108057 was an open-label, repeat-dose study which evaluated the efficacy, safety and consistency of response following repeated, intermittent, short-term dosing of Revolade over 3 cycles of therapy in adults with previously treated ITP. A cycle was defined as an up to 6-week on-therapy period followed by an up to 4-week off-therapy period. The duration of both the on-therapy and the off-therapy periods was defined by the patient's platelet count. Patients were to interrupt treatment for the cycle if they achieved a platelet count >200,000/microL, or when they reached Week 6. Patients were to begin the next cycle when their platelet counts fell below 20,000/microL, or when they reached Week 4 of the off-therapy period. The primary endpoint was the proportion of patients who achieved a platelet count ≥ 50,000/microL and at least 2 x baseline in Cycle 2 or 3, given this response in Cycle 1.

**Table 17          Evaluable and responding patients in TRA108057 (REPEAT)**

|                                                       | Revolade 50 mg (N=66) |
| ----------------------------------------------------- | --------------------- |
| Evaluable in Cycle 1, n                               | 65                    |
| Responders in Cycle 1, n (%)                          | 52 (80)               |
| Evaluable in Cycle 2 or 3, n                          | 52                    |
| Responders in Cycle 1 and in Cycle 2 or 3, n (%)      | 45 (87)               |
| Proportion                                            | 0.87                  |
| 95% CI for Proportion (Exact Methods)                 | (0.74, 0.94)          |

Of the 52 patients who responded in Cycle 1, 33 (63%) achieved a platelet count of ≥50,000/ microL and at least 2 x baseline on Day 8 in Cycle 1; on Day 15, 37 (79%) of 47 evaluable patients achieved this level of response.

A reduction in any bleeding (WHO Grade 1-4) and clinically significant bleeding (WHO Grade 2-4) during the treatment phases was demonstrated in each cycle. At the baseline visit of Cycle 1, 50% and 19% of patients reported any bleeding and clinically significant bleeding, respectively. At the Day 43 Visit of Cycle 1, the proportion of patients bleeding was reduced; 12% and 0% of patients reported any bleeding and clinically significant bleeding. Similar results were found during the subsequent treatment cycles.

Eight patients successfully managed 10 hemostatic challenges without need for additional therapy to elevate platelet counts and without unexpected bleeding.

*TRA105325 (EXTEND):*

TRA105325 was an open label extension study which has evaluated the safety and efficacy of Revolade in patients with ITP at least 6 months from diagnosis who were previously enrolled in a Revolade study. In this study, patients were permitted to modify their dose of study medication as well as decrease or eliminate concomitant ITP medications.

Revolade was administered to 302 ITP patients; 218 completed 1 year of treatment, 180 completed 2 years, 107 completed 3 years, 75 completed 4 years, 34 completed 5 years and 18 completed 6 years of therapy. The median baseline platelet count was 19,000/microL prior to Revolade administration. Median platelet counts at 1, 2, 3, 4, 5, 6 and 7 years on study were 85,000/microL, 85,000/microL, 105,000/microL, 64,000/microL, 75,000/microL, 119,000/microL and 76,000/microL respectively. The median daily dose of Revolade following 6 months of therapy was 50 mg (n=74).

At baseline, 59% of patients had any bleeding (WHO Bleeding Grades 1-4) and 18% had clinically significant bleeding (WHO Bleeding Grades 2-4 indicating clinically significant bleeding). The proportion of patients with any bleeding and clinically significant bleeding decreased from baseline by approximately 50% for the majority of assessments up to 1 year.

One-hundred and one patients were taking ITP medications at baseline upon entry into EXTEND study, and 39 patients were able to permanently discontinue or achieve a sustained reduction of at least one baseline ITP medication without needing rescue medication. Sixty-five percent of these patients maintained this discontinuation or reduction for at least 24 weeks. Sixty-one percent of patients completely discontinued at least one baseline ITP medication, and

55% of patients permanently discontinued all baseline ITP medications, without subsequent rescue treatment.

Twenty-four patients experienced at least one hemostatic challenge during the study. No patient experienced unexpected bleeding complications related to the procedure while on study.

*CETB115J2411 (TAPER)*

CETB115J2411 was a single-arm phase II study including ITP patients treated with Revolade after first-line corticosteroid failure irrespective of time since diagnosis. A total of 105 patients were enrolled in the study and started treatment with Revolade 50 mg once daily (25 mg once daily for patients of East-/Southeast Asian ancestry except for Japanese patients in Japan who received 12.5 mg once daily). The dose of Revolade was adjusted during the treatment period based on individual platelet counts with the goal to achieve a platelet count ≥100,000/microL.

Of the 126 patients that were screened for inclusion in the TAPER study, 105 patients received at least one dose of Revolade, 70 patients (66.7%) completed treatment and 35 patients (33.3%) discontinued treatment early.

*Primary analysis results of sustained response off treatment.*

Patients who reached a platelet count of ≥100,000/microL and maintained platelet counts for 2 months ≥70,000/microL were eligible for tapering off Revolade and treatment discontinuation. To be considered as having achieved a sustained response off treatment, a patient had to maintain platelet counts ≥30,000/microL, in the absence of bleeding adverse events or any rescue therapy, both during the treatment tapering period and following discontinuation of treatment until Month 12.

The tapering schedule recommended dose reductions of 25 mg every 2 weeks, if the platelet counts were stable, followed by dosing at 25 mg on alternate days for 2 weeks until treatment discontinuation.

The duration of tapering was individualized depending on the starting dose and the response of the patient. The tapering was done in smaller drug decrements of 12.5 mg every second week for patients of East/Southeast Asian ancestry. If a relapse (defined as platelet count <30,000/microL) occurred during the 12-month treatment period, patients were offered a new course of Revolade at the appropriate starting dose.

The study met the primary objective by demonstrating that Revolade was able to induce sustained response off treatment, in the absence of bleeding events or the use of rescue therapy, by Month 12 in 32 patients of the 105 enrolled patients (30.5%; p<0.0001; 95% CI: 21.9, 40.2).

Eighty-nine patients (84.8%) achieved a complete response (platelet count ≥100,000/microL) and 65 patients (61.9%) maintained the complete response for at least 2 months with no platelet counts <70,000/microL. Forty-four patients (41.9%) were able to be tapered off Revolade through treatment discontinuation while maintaining platelet counts ≥30,000/microL in the absence of bleeding adverse events or any rescue therapy (Table 18).

The median duration of sustained response after treatment discontinuation to Month 12 was 33.3 weeks (min-max: 4-51).

The overall safety analysis is consistent with previously reported data and the risk benefit assessment remained unchanged for the use of eltrombopag in patients with ITP.

**Table 18     Proportion of patients with sustained response off treatment at month 12 (Full Analysis Set) in Taper**

| | | All patients N=105 | | Hypothesis Testing | |
|---|---|---|---|---|---|
| | | n (%) | 95% CI | p-value | Reject H0 |
| Step 1: | Patients who reached platelet count ≥100,000/microL at least once | 89 (84.8) | (76.4, 91.0) | | |
| Step 2: | Patients who maintained stable platelet count for 2 months after reaching 100,000/microL (no counts below 70,000/microL) | 65 (61.9) | (51.9, 71.2) | | |
| Step 3: | Patients who were able to be tapered off the drug through treatment discontinuation, maintaining platelet count ≥30,000/microL in the absence of bleeding adverse events or use of any rescue therapy | 44 (41.9) | (32.3, 51.9) | | |
| Step 4: | Patients with sustained response off treatment until Month 12, maintaining platelet count ≥30,000/microL in the absence of bleeding adverse events or use of any rescue therapy | 32 (30.5) | (21.9, 40.2) | <0.0001* | Yes |

*N: The total number of patients in the treatment group. It is the denominator for percentage (%) calculation.*

*n: Number of patients in the corresponding category.*

*The 95% CI for the frequency distribution was computed using Clopper-Pearson exact method.*

*Clopper Pearson test is used for testing whether the proportion of responders is greater than 15%.*

*CI and p-values are reported.*

*\* Indicates statistical significance (one-sided) at the 0.05 level.*

*Results of an early response on treatment analysis by time since ITP diagnosis.*

An ad-hoc analysis was conducted on the n=105 patients by time since ITP diagnosis to assess the early response to Revolade treatment across four different ITP duration categories (newly diagnosed ITP <3 months, persistent ITP 3 to <6 months, persistent ITP 6 to ≤12 months, and chronic ITP >12 months).

49% of patients (n=51) had an ITP duration of <3 months, 20% (n=21) of 3 to <6 months, 17% (n=18) of 6 to ≤12 months and 14% (n=15) of >12 months.

Until the cut-off date (22-Oct-2021), patients were exposed to Revolade for a median (25th to 75th percentile) duration of 6.2 months (2.3 to 12.0). The median (25th to 75th percentile) platelet count at baseline was 16,000/microL (7,800 to 28,000/microL).

Platelet count response, defined as a platelet count ≥50,000/microL at least once by Week 9 without rescue therapy was achieved in 84% (95% CI: 71%, 93%) of newly diagnosed patients (ITP duration <3 months), 91% (95% CI: 70%, 99%) and 94% (95% CI: 73%, 100%) of persistent ITP patients (i.e., with ITP diagnosis 3 to <6 months and 6 to ≤12 months, respectively), and in 87% (95% CI: 60%, 98%) of chronic ITP patients.

The rate of complete response, defined as platelet count ≥100,000/microL at least once by Week 9 without rescue therapy, was 75% (95% CI: 60%, 86%) in newly diagnosed patients (ITP duration <3 months), 76% (95% CI: 53%, 92%) and 72% (95% CI: 47%, 90%) in persistent ITP patients (ITP duration 3 to <6 months and 6 to ≤12 months, respectively), and 87% (95% CI: 60%, 98%) in chronic ITP patients.

The rate of durable platelet count response, defined as a platelet count ≥50,000/microL for at least 6 out of 8 consecutive assessments without rescue therapy during the first 6 months on study, was 71% (95% CI: 56%, 83%) in newly diagnosed ITP patients (ITP duration <3 months), 81% (95% CI: 58%, 95%) and 72% (95% CI: 47%, 90%) in persistent ITP patients (ITP duration 3 to <6 months and 6 to ≤12 months, respectively), and 80% (95% CI: 52%, 96%) in chronic ITP patients.

When assessed with the WHO Bleeding Scale, the proportion of newly diagnosed and persistent ITP patients without bleeding at Week 4 ranged from 88% to 95% compared to 37% to 57% at baseline. For chronic ITP patients it was 93% compared to 73% at baseline.

The safety of Revolade was consistent across all ITP categories and in line with its known safety profile.

## Pediatric patients (aged 1 to 17 years)

The safety and efficacy of Revolade in pediatric patients with previously treated ITP have been demonstrated in two studies.

## Double-blind placebo-controlled studies

### TRA115450 (PETIT2):

The primary endpoint was a sustained response, defined as the proportion of patients receiving Revolade, compared to placebo, achieving platelet counts ≥50,000/microL for at least 6 out of 8 weeks (in the absence of rescue therapy), between Weeks 5 to 12 during the double-blind randomized period. Patients were refractory or relapsed to at least one prior ITP therapy or unable to continue other ITP treatments for a medical reason and had platelet count <30,000/microL. Ninety-two patients were randomized by three age cohort strata (2:1) to Revolade (n=63) or placebo (n=29). The dose of Revolade could be adjusted based on individual platelet counts.

Overall, a significantly greater proportion of Revolade patients (40%) compared with placebo patients (3%) achieved the primary endpoint (OR: 18.0 (95% CI: 2.3, 140.9) p< 0.001) which was similar across the three age cohorts (Table 19).

**Table 19**      **Sustained platelet response rates by age cohort in pediatric patients with ITP at least 12 months from diagnosis in PETIT2**

|  | Revolade<br>n/N (%) [95% CI] | Placebo<br>n/N (%) [95% CI] |
|---|---|---|
| Cohort 1 (12 to 17 years) | 9/23 (39%) [20%, 61%] | 1/10 (10%) [0%, 45%] |
| Cohort 2 (6 to 11 years) | 11/26 (42%) [23%, 63%] | 0/13 (0%) [N/A] |
| Cohort 3 (1 to 5 years) | 5/14 (36%) [13%, 65%] | 0/6 (0%) [N/A] |

A significantly greater proportion of patients treated with Revolade (75%) compared with placebo (21%) had a platelet response (at least one platelet count >50,000/microL during the first 12 weeks of randomized treatment in absence of rescue therapy) (OR: 11.7, (95% CI: 4.0, 34.5), p <0.001). The proportion of patients who responded to Revolade in the open-label 24-week period (80%) was similar to that observed during the randomized portion of the study.

Statistically fewer Revolade patients required rescue treatment during the randomized period compared to placebo patients (19% (12/63) vs. 24% (7/29), p=0.032).

At baseline, 71% of patients in the Revolade group and 69% in the placebo group reported any bleeding (WHO Grades 1-4). At Week 12, the proportion of Revolade patients reporting any bleeding was decreased to half of baseline (36%). In comparison, at Week 12, 55% of placebo patients reported any bleeding.

Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the study and 53% (8/15) of patients were able to reduce (n=1) or discontinue (n=7) baseline ITP therapy, mainly corticosteroids, without needing rescue therapy.

*TRA108062 (PETIT)*:

The primary endpoint was the proportion of patients achieving platelet counts ≥50,000/microL at least once between Weeks 1 and 6 of the randomized period. Patients were refractory or relapsed to at least one prior ITP therapy with a platelet count <30,000/microL (n=67). During the randomized period of the study, patients were randomized by 3 age cohort strata (2:1) to Revolade (n=45) or placebo (n=22). The dose of Revolade could be adjusted based on individual platelet counts.

Overall, a significantly greater proportion of Revolade patients (62%) compared with placebo patients (32%) met the primary endpoint (OR: 4.3 (95% CI: 1.4, 13.3) p=0.011). Table 20 shows platelet response across the three age cohorts.

**Table 20**     **Platelet response rates in pediatric patients with ITP at least 6 months from diagnosis in PETIT**

|  | Revolade<br>n/N (%) [95% CI] | Placebo<br>n/N (%) [95% CI] |
|---|---|---|
| Cohort 1 (12 to 17 years) | 10/16 (62%) [35%, 85%] | 0/8 (0%) [N/A] |
| Cohort 2 (6 to 11 years) | 12/19 (63%) [44%, 90%] | 3/9 (33%) [7%, 70%] |
| Cohort 3 (1 to 5 years) | 6/10 (60%) [26%, 88%] | 4/5 (80%) [28%, 99%] |

A significantly greater proportion of patients treated with Revolade (36%) compared with placebo (0%) had a platelet response (platelet counts >50,000/microL for at least 60% of assessments between Weeks 2 and 6) (OR: 5.8, (95% CI: 1.2, 28.9), p=0.002).

Statistically fewer Revolade-treated patients required rescue treatment during the randomized period compared to placebo-treated patients (13% (6/45) vs. 50% (11/22), p=0.002).

At baseline, 77.7% of patients in the Revolade group and 81.8% in the placebo group reported any bleeding (WHO Grades 1-4). The proportion of Revolade patients reporting any bleeding decreased to 22.2% at Week 6. In comparison, 72.7% of placebo patients reported any bleeding at Week 6.

Patients were permitted to reduce or discontinue baseline ITP therapy only during the open-label phase of the study and 46% (6/13) of patients were able to reduce (n=3) or discontinue (n=3) baseline ITP therapy, mainly corticosteroids, without needing rescue therapy.

## Chronic hepatitis C associated thrombocytopenia studies

The efficacy and safety of Revolade for the treatment of thrombocytopenia in patients with HCV infection were evaluated in two randomized, double-blind, placebo-controlled studies. ENABLE 1 utilized peginterferon alfa-2a plus ribavirin for antiviral treatment and ENABLE 2 utilized peginterferon alfa-2b plus ribavirin. In both studies, patients with a platelet count of <75,000/microL were enrolled and stratified by platelet count (<50,000/microL and ≥50,000/microL to <75,000/microL), screening HCV RNA (<800,000 IU/mL and ≥800,000 IU/mL), and HCV genotype (genotype 2/3, and genotype 1/4/6).

The studies consisted of two phases-a pre-antiviral treatment phase and an antiviral treatment phase. In the pre-antiviral treatment phase, patients received open-label Revolade to increase the platelet count to ≥90,000/microL for ENABLE 1 and ≥100,000/microL for ENABLE 2. Revolade was administered at an initial dose of 25 mg once daily for 2 weeks and increased in 25 mg increments over 2 to 3 week periods to achieve the required platelet count for phase 2 of the study. The maximal time patients could receive open-label Revolade was 9 weeks. If sufficient platelet counts were achieved, patients were randomized (2:1) to the same dose of Revolade at the end of the pre-treatment phase or to placebo. Revolade was administered in combination with antiviral treatment per their respective prescribing information for up to 48 weeks.

The primary efficacy endpoint for both studies was sustained virological response (SVR), defined as the percentage of patients with no detectable HCV-RNA at 24 weeks after completion of the planned treatment period. Approximately 70% of patients were genotype 1/4/6 and 30% were genotype 2/3. Approximately 31% of patients had been treated with prior HCV therapies, primarily pegylated interferon plus ribavirin. The median baseline platelet counts (approximately 60,000/microL) were similar among all treatment groups. The median time to achieve the target platelet count ≥90,000/microL (ENABLE 1) or ≥100,000/microL (ENABLE 2) was 2 weeks.

In both HCV studies, a significantly greater proportion of patients treated with Revolade achieved SVR compared to those treated with placebo (see Table21). Significantly fewer patients treated with Revolade had any antiviral dose reductions compared to placebo. The proportion of patients with no antiviral dose reductions was 45% for Revolade compared to 27% for placebo. Significantly fewer patients treated with Revolade prematurely discontinued antiviral therapy compared to placebo (45% vs. 60%, p= <0.0001). The majority of patients treated with Revolade (76%) had minimum platelet counts that were ≥50,000/microL compared to 19% for placebo. A greater proportion of patients in the placebo group (20%) had minimum platelet counts fall below 25,000/microL during treatment compared to the Revolade group (3%). In the Revolade group, SVR rates in patients with high viral loads (>800,000) were 18% as compared to 8% in the placebo group. Significantly more patients reached the later antiviral milestones of early virologic response (EVR), complete early virologic response (cEVR), end of treatment response (ETR) and sustained virologic response at 12-week follow-up (SVR12) when treated with Revolade.

**Table 21      ENABLE 1 and ENABLE 2 virologic response**

| | ENABLE 1[a] | | ENABLE 2[b] | |
|---|---|---|---|---|
| **Pre-antiviral Treatment Phase** | N=715 | | N=805 | |
| % Achieving target platelet counts and initiating antiviral therapy [c] | 95% | | 94% | |
| | **Revolade** | **Placebo** | **Revolade** | **Placebo** |
| **Antiviral Treatment Phase** | **n=450** %  | **n=232** % | **n=506** % | **n=253** % |
| **Overall SVR** [d] | 23 | 14 | 19 | 13 |
| HCV Genotype 2,3 | 35 | 24 | 34 | 25 |
| HCV Genotype 1,4,6 | 18 | 10 | 13 | 7 |
| **Overall EVR** [d] | 66 | 50 | 62 | 41 |
| HCV Genotype 2,3 | 84 | 67 | 83 | 56 |
| HCV Genotype 1,4,6 | 58 | 41 | 53 | 34 |

a    Revolade given in combination with peginterferon alfa-2a (180 microg once weekly for 48 weeks for genotypes 1 or 4; 24 weeks for genotype 2 or 3) plus ribavirin (800 to 1200 mg daily in 2 divided doses orally)

b    Revolade given in combination with peginterferon alfa-2b (1.5 microg/kg once weekly for 48 weeks for genotype 1; 24 weeks for genotype 2 or 3) plus ribavirin (800 to 1400 mg orally)

c    Target platelet count was ≥90,000/microL for ENABLE 1 and ≥100,000/microL for ENABLE 2.

d    *P* value <0.05 for Revolade versus placebo

## Definitive immunosuppressive therapy-naïve severe aplastic anemia study

CETB115AUS01T

Revolade in combination with horse antithymocyte globulin (h-ATG) and cyclosporine was investigated in a single-arm, single-center, open-label, sequential cohort study in patients with severe aplastic anemia who had not received prior definitive immunosuppressive therapy (i.e., ATG therapy, alemtuzumab, or high dose cyclophosphamide). The multiple cohorts differed by treatment start day and duration of Revolade-treatment and the initiation of low dose of cyclosporine (maintenance dose) for patients who achieved a hematologic response at 6 months. A total of 153 patients received Revolade in sequential cohorts:

- Revolade on Day 14 to Month 6 (D14-M6) plus h-ATG and cyclosporine (Cohort 1 regimen, n=30).

- Revolade on Day 14 to Month 3 (D14-M3) plus h-ATG and cyclosporine (Cohort 2 regimen, n=31), with half of the patients eligible to receive low dose of cyclosporine (maintenance dose) if they achieved a hematologic response at 6 months.

- Revolade on Day 1 to Month 6 (D1-M6) plus h-ATG and cyclosporine (Cohort 3 regimen, n=92), with all patients eligible to receive low dose of cyclosporine (maintenance dose) if they achieved a hematologic response at 6 months.

The starting dose of Revolade for adults and pediatric patients aged 12 to 17 years was 150 mg once daily (a reduced dose of 75 mg was administered for East-/Southeast-Asians), 75 mg once daily for patients aged 6 to 11 years (a reduced dose of 37.5 mg was administered for East-/Southeast-Asians), and 2.5 mg/kg once daily for patients aged 2 to 5 years (a reduced dose of

1.25 mg/kg was administered for East-/Southeast-Asians). The dose of Revolade was reduced if the platelet count exceeded 200,000/microL and interrupted and reduced if it exceeded 400,000/microL.

All patients received h-ATG 40 mg/kg/day on Days 1 to 4 of the 6-month treatment period and a total daily dose of 6 mg/kg/day of cyclosporine for 6 months in patients aged 12 years and older or a total daily dose of 12 mg/kg/day for 6 months in patients aged 2 to 11 years. A 2 mg/kg/day maintenance dose of cyclosporine was administered for an additional 18 months to 15 patients who achieved a hematologic response at 6 months in the Revolade D14-M3 cohort and all patients who achieved a hematologic response at 6 months in the Revolade D1-M6 cohort.

Data from the recommended schedule of Revolade on Day 1 to Month 6 in combination with h-ATG and cyclosporine (Cohort 3 regimen) are presented below. This cohort had the highest complete response rates.

In the Revolade D1-M6 cohort, the median age was 28.0 years (range 5 to 82 years) with 16.3% and 28.3% of patients ≥65 years of age and <18 years of age, respectively. 45.7% of patients were male and the majority of patients were White (62.0%).

The efficacy of Revolade in combination with h-ATG and cyclosporine was established on the basis of complete hematological response at 6 months. A complete response was defined as hematological parameters meeting all 3 of the following values on 2 consecutive serial blood count measurements at least one week apart: absolute neutrophil count (ANC) >1,000/microL, platelet count >100,000/microL and hemoglobin >10 g/dL. A partial response was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in severe aplastic anemia equivalent to 2 of the following values on 2 consecutive serial blood count measurements at least one week apart: ANC >500/microL, platelet count >20,000/microL, or reticulocyte count >60,000/microL.

**Table 22        Efficacy results in definitive immunosuppressive therapy-naïve SAA patients**

| | Rev D1-M6 + h-ATG + cyclosporine N=92 |
|---|---|
| **Month 3, n[a]** | **88** |
| Overall response, n (%) [95% CI] | 66 (75.0) [64.6, 83.6] |
| Complete response, n (%) [95% CI] | 24 (27.3) [18.3, 37.8] |
| **Month 6, n[a]** | **87** |
| Overall response, n (%) [95% CI] | 69 (79.3) [69.3, 87.3] |
| Complete response, n (%) [95% CI] | 38 (43.7) [33.1, 54.7] |
| Median duration of overall response, n[b] | 70 |
| Months (95% CI) | 24.3 (21.4, NE) |
| Median duration of complete response, n[b] | 46 |
| Months (95% CI) | 24.3 (23.0, NE) |
| [a] The number of patients who reached the 3- or 6-month assessment or withdrew earlier is the denominator for percentage calculation | |

| | Rev D1-M6 + h-ATG + cyclosporine N=92 |
|---|---|
| *b Number of responders at any time* <br> *NE = not estimable* | |

The overall and complete hematological response rates at Year 1 (N=78) are 56.4% and 38.5% and at Year 2 (N=62) are 38.7% and 30.6%, respectively.

*Pediatric patients*

Thirty-seven patients aged 2 to 17 years were enrolled in the single-arm, sequential-cohort study. Of the 36 patients who reached the 6-month assessment point or withdrew earlier, the complete response rate at 6 months was 30.6% (0/2 in patients aged 2 to 5 years, 1/12 in patients aged 6 to 11 years, and 10/22 in patients aged 12 to 17 years) and the overall response rate at 6 months was 72.2% (2/2 in patients aged 2 to 5 years, 7/12 in patients aged 6 to 11 years, and 17/22 in patients aged 12 to 17 years). Out of 25 evaluable patients in the Revolade D1-M6 cohort, the complete response rate at 6 months was 28% (7/25) and the overall response rate at 6 months was 68.0%.

## Refractory severe aplastic anemia study

CETB115AUS28T

Revolade was studied in a single-arm, single-center open-label study in 43 patients with severe aplastic anemia who had an insufficient response to at least one prior immunosuppressive therapy and who had a platelet count ≤30,000/microL.

Revolade was administered at an initial dose of 50 mg once daily for 2 weeks and increased over 2 week periods up to a maximum dose of 150 mg once daily. The primary endpoint was hematological response assessed after 12 weeks of Revolade treatment.

Revolade was discontinued after 16 weeks if no hematological response or transfusion independence was observed. Patients who responded continued therapy in an extension phase of the study.

Hematological response was defined as meeting one or more of the following criteria: 1) platelet count increases to 20,000/microL above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks; 2) hemoglobin increase by >1.5 g/dL (for patients with pre-treatment hemoglobin <9 g/dL), or a reduction in the volume of RBC transfusions of at least 4 units for 8 consecutive weeks; 3) absolute neutrophil count (ANC) increase of 100% (for patients with pre-treatment ANC <500/microL) or an ANC increase >500/microL.

The treated population had median age of 45 years (range 17 to 77 years) and 56% of patients were male. At baseline the median platelet count was 20,000/microL hemoglobin was 8.4 g/dL, and ANC was 580/microL. Eighty-six percent of patients were RBC transfusion dependent, and 91% were platelet transfusion dependent. The majority of patients (84%) had received at least 2 prior immunosuppressive therapies. Three patients had cytogenetic abnormalities at baseline.

A total of 17 patients (40%) met the hematologic response criteria in at least 1 lineage at the Primary Response Assessment (95% CI: 25, 56).

Multi-lineage responses were observed in 4/17 responders (24%) at the initial response assessment and in 9/17 responders (53%) at last assessment. Of the five patients who met protocol specified 'tri-lineage hematopoiesis' criteria for at least eight weeks and were tapered off Revolade, all five patients have maintained tri-lineage hematopoiesis since discontinuing treatment for a median follow up period of 20.6 months (range 5.7 to 22.5 months).

The majority of responders met platelet response criteria (65%), followed by neutrophil and hemoglobin response criteria (47% and 18% respectively). The 15 responders who had at least 2 response assessments were evaluable for assessment of response duration and had a median duration of response of 12.0 months.

Nine of the 17 responders had a multi-lineage best response. Of the 14 patients who entered the extension, seven had improvements in more than one lineage following continuation of treatment: five patients with uni-lineage response improved to multi-lineage response (bi- or tri-lineage) and two patients with bi-lineage response improved to tri-lineage response. Three of the four bi-lineage responders also had meaningful improvements in hemoglobin (>1.5 g/dL); however, as their baseline hemoglobin was above 9 g/dL they are not counted as having an erythroid response.

The longest platelet transfusion free period in responders ranged from 8 to 1,190 days with a median of approximately 287 days. The longest RBC transfusion free period in responders ranged from 15 to 1,190 days with a median of approximately 266 days. Of the five patients who met protocol specified 'tri-lineage hematopoiesis' criteria for at least eight weeks and were tapered off Revolade, all five patients have maintained tri-lineage hematopoiesis since discontinuing treatment for a median follow up period of 20.6 months (range 5.7 to 22.5 months).

## NON-CLINICAL SAFETY DATA

### Safety pharmacology and repeat dose toxicity

Treatment-related cataracts were detected in rodents and were dose and time-dependent. At ≥6 times the human clinical exposure based on AUC in ITP patients at 75 mg/day and 3 times the human clinical exposure based on AUC in HCV patients at 100 mg/day, cataracts were observed in mice after 6 weeks and rats after 28 weeks of dosing. At ≥4 times the human clinical exposure based on AUC in ITP patients at 75 mg/day and 2 times the human clinical exposure based on AUC in HCV patients at 100 mg/day, cataracts were observed in mice after 13 weeks and in rats after 39 weeks of dosing. At non-tolerated doses in pre-weaning juvenile rats dosed from Days 4-32 (approximately equating to a 2-year old human at the end of the dosing period), ocular opacities were observed (histology not performed) at 9 times the maximum human clinical exposure in pediatric ITP patients at 75 mg/day, based on AUC. However, cataracts were not observed in juvenile rats given tolerated doses at 5 times the human clinical exposure in pediatric ITP patients, based on AUC. Cataracts have not been observed in dogs after 52 weeks of dosing at 2 times the human clinical exposure in ITP patients at 75 mg/day and equivalent to the human clinical exposure in HCV patients at 100 mg/day, based on AUC (see section WARNINGS AND PRECAUTIONS).

Renal tubular toxicity was observed in studies of up to 14 days duration in mice and rats at exposures that were generally associated with morbidity and mortality. Tubular toxicity was

also observed in a 2-year oral carcinogenicity study in mice at doses of 25, 75 and 150 mg/kg/day. Effects were less severe at lower doses and were characterized by a spectrum of regenerative changes. The exposure at the lowest dose was 1.2 times the human clinical exposure based on AUC in ITP patients at 75 mg/day and 0.6 times the human clinical exposure based on AUC in HCV patients at 100 mg/day. Renal effects were not observed in rats after 28 weeks or in dogs after 52 weeks at exposures 4 and 2 times the human clinical exposure in ITP patients at 75 mg/day, respectively and 2 times and equivalent to the human clinical exposure in HCV patients at 100 mg/day, respectively based on AUC.

### Carcinogenicity and mutagenicity

Eltrombopag was not carcinogenic in mice at doses up to 75 mg/kg/day or in rats at doses up to 40 mg/kg/day (exposures up to 4 and 5 times the human clinical exposure based on AUC in ITP patients at 75 mg/day and 2 times the human clinical exposure based on AUC in HCV patients at 100 mg/day). Eltrombopag was not mutagenic or clastogenic in a bacterial mutation assay or in two *in vivo* assays in rats (micronucleus and unscheduled DNA synthesis, 10 times the human clinical exposure, based on Cmax in ITP patients at 75 mg/day and 7 times the human clinical exposure in HCV patients at 100 mg/day). In the *in vitro* mouse lymphoma assay, eltrombopag was marginally positive (<3-fold increase in mutation frequency). These *in vitro* and *in vivo* findings suggest that eltrombopag does not pose a genotoxic risk to humans.

### Reproductive toxicity

Eltrombopag did not affect female fertility in rats at doses up to 20 mg/kg/day (2 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and similar to the human clinical exposure based on AUC in patients with chronic hepatitis C at 100 mg/day). Eltrombopag did not affect male fertility in rats at doses up to 40 mg/kg/day, the highest dose tested (3 times the human clinical exposure based on AUC in patients with ITP at 75 mg/day and 2 times the human clinical exposure based on AUC in patients with chronic hepatitis C at 100 mg/day) (see also section FEMALES AND MALES OF REPRODUCTIVE POTENTIAL).

### Juvenile animal studies

At non-tolerated doses in pre-weaning rats, ocular opacities were observed. However, at tolerated doses, no ocular opacities were observed (see section NON-CLINICAL SAFETY DATA, Safety pharmacology and repeat dose toxicity). There are no findings in juvenile rats to suggest a greater risk of toxicity with eltrombopag treatment in pediatric vs. adult patients.

## INCOMPATIBILITIES

No known incompatibilities

## STORAGE

See folding box.

Revolade should not be used after the date marked "EXP" on the pack.

Revolade must be kept out of the reach and sight of children.

## Nature and Contents of Container

Each cardboard box contains 2, 4 or 12 blisters (PA/AL/PVC - AL) of 7 tablets

Not all presentations are available in every country.

## INSTRUCTIONS FOR USE AND HANDLING

No special requirements.

### Special precautions for disposal

No special precautions for disposal.

### Manufacturer:

See folding box.

### International Package Leaflet

Information issued: September 2022

® = Registered trademark

## Novartis Pharma AG, Basel, Switzerland